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ABSTRACT
Bioengineering the Expression of Active Recombinant Human Cathepsin G, Enteropeptidase,
Neutrophil Elastase, and C-Reactive Protein in Yeast
by
Eliot T. Smith
The yeasts Pichia pastoris and Kluyveromyces lactis were used to express several recombinant
human proteins for further biochemical characterization. Two substitution variants of
recombinant human enteropeptidase light chain (rhEPL) were engineered to modify the extended
substrate specificity of this serine protease. Both were secreted as active enzymes in excess of
1.7 mg/L in P. pastoris fermentation broth. The substitution variant rhEPL R96Q showed
significantly reduced specificities for the preferred substrate sequences DDDDK and DDDDR;
however, the rhEPL Y174R variant displayed improved specificities for these substrate
sequences relative to all other reported variants of this enzyme. The neutrophil serine proteases
human cathepsin G (hCatG) and human neutrophil elastase (HNE) were expressed in P. pastoris
and HNE was also expressed in K. lactis. The recombinant variants rhCatG and rHNE, with
intact C-terminal extensions, were expressed as fusion proteins with the soluble heme-binding
domain of cytochrome B5 (CytB5) and an N-terminal hexahistidine (6xHis) tag for purification.
The CytB5 domain was linked to the native N-termini of active rhCatG and rHNE by the EPLcleavable substrate sequence DDDDK~I, where ~ is the sessile bond. These fusion proteins
were directed for secretion. The yeast P. pastoris expressed up to 3.5 mg/L of EPL-activable
rHNE in fermentation broth; however, only 200 µg/L of rhCatG could be produced by this
method. Recombinant expression in K. lactis never surpassed 100 µg/L of activable rHNE. The
CytB5 fusion domain was present in the heme-bound form, conferring a red color and 410 nm
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absorbance peak to solutions containing the fusion proteins. This absorbance pattern was most
readily visible during the purification of CytB5-rHNE from P. pastoris. Human C-reactive
protein (hCRP) and the substitution variant CRP E42Q were expressed in recombinant form and
secreted by P. pastoris. Both products were found to bind phosphocholine (PCh) in the same
manner as native hCRP. Difficulties encountered during purification revealed that wild type
recombinant CRP (rCRP) was produced at 2 different molecular masses. The P. pastoris
recombinant expression system yielded better results than K. lactis. Bioreactor-scale
fermentation in a 5 L vessel facilitated expression and characterization of these recombinant
proteins.
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CHAPTER 1
INTRODUCTION

Recombinant Protein Engineering
Recombinant protein expression has emerged as a powerful tool for the biomedical
sciences during the past several decades. Researchers began using recombinant DNA
technologies to reprogram Escherichia coli for protein expression in the 1970s (Marians et al.
1976; Wood and Lee 1976; Itakura et al. 1977; Meagher et al. 1977; Miller et al. 1977a; Miller et
al. 1977b). Recombinant human insulin produced in E. coli was first approved by the FDA for
therapeutic use in 1983 (Johnson 1983) and has since supplanted native porcine and bovine
insulin as the preferred source of the drug. In the decades since this innovation, the
pharmaceutical industry has heavily pursued recombinant proteins as novel approaches to the
treatment of many diseases.
Recombinant protein expression technologies now enable a plethora of otherwise
impossible experimental approaches. Recombinant human proteins are often produced in large
quantities for further experimentation. Amino acid sequences are modified to study the
contributions of individual residues to protein structures and functions. Multiple protein
domains with distinct properties can be coupled into fusion constructs that exhibit combined
traits of the individual component proteins, a strategy that can be used to facilitate detection and
purification. Novel proteins can even be invented de novo, a promising science that is still in its
infancy (Koga et al. 2012). These pursuits, among many others that have evolved out of
recombinant protein expression technologies, continue to provide new methods for biomedical
research and yield novel medical treatments.
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The general approach to recombinant protein expression begins with the molecular
cloning of protein-coding DNA into a genetic vector and delivery of this programing into a
suitable host organism (Marians et al. 1976; Wood and Lee 1976; Itakura et al. 1977; Meagher et
al. 1977; Miller et al. 1977a; Miller et al. 1977b). The transformed host can then express the
encoded protein; however, the specific nature of any recombinant expression depends on the
interplay of several factors including the traits of the chosen host organism, the nature of the
genetic program, and the properties of the recombinant protein.

Recombinant Expression Systems
Many organisms are useful as hosts for recombinant protein expression, including
especially bacterial, animal, and yeast cell types. With distinct biological properties, each of
these expression systems behaves differently and each is best suited to different project goals.
Successful expression requires consideration of many factors in selecting an appropriate host
organism as an expression platform.
Bacterial Systems. E. coli strains are the most commonly used host organisms because
they are prokaryotes and possess a simple genetic system. The native genetics of these bacteria
have been well-characterized and the genome sequences of many E. coli strains are available
through the National Center for Biotechnology Information (NCBI) database. Recombinant
DNA is typically introduced using plasmid vectors that are easily manipulated with standard
molecular cloning techniques. E. coli can be transformed by electroporation or chemical means
and transformants are routinely screened by overnight growth with antibiotic resistance selection
on lysogeny broth (LB) agar plates. Liquid cultures of E. coli grow quickly, can grow to high
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cell densities, and generate large quantities of protein under proper conditions, thus these
cultures are suitable for batch fermentation on an industrial scale.
E. coli do not contain the machinery required for eukaryotic post-translational processing
steps like chaperone-aided folding, disulfide bond formation, glycosylation, and trafficking;
consequently, large and complex proteins often express poorly in E. coli, commonly forming
inclusion bodies within the cytosol. These aggregates of insoluble, misfolded protein must be
isolated from the lysed cells, solubilized, and refolded. Such complicated processing can be
difficult and time consuming, can require harsh chemical treatments and can significantly reduce
the amount of functional protein that is recovered. Despite these drawbacks, E. coli strains
remain the first choice for many recombinant protein engineers due to organism simplicity, ease
of manipulation, rapid growth, and industrial scalability.
Animal Systems. In contrast to the simplicity of E. coli, animal cell lines, which are
equipped with eukaryotic machinery, provide co- and post-translational processing that may be
necessary for successful expression of many human proteins. The variety of available
mammalian cell types offers more options for customizing the expression system to the specific
requirements of the target protein and the project. This can be necessary for studies that require
proteins to be produced in their native environs, such as experiments on trafficking, multienzyme
pathways, and membrane-associated proteins.
Despite these advantages, expression systems based on animal cell lines suffer from
many drawbacks. Stable, permanent genetic manipulations do not occur as readily in animal
cells as they do in many microorganisms, making transformants more difficult to generate.
Many animal cell lines do not grow in suspension and require an adherent surface; furthermore,
such cell lines grow slowly and are poorly suited for industrial scalability. Even cell lines that do
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grow in suspension and scale well for industrial purposes typically need complex growth media,
often containing fetal bovine serum (FBS) and other specialized components that
microorganisms do not require. Total protein yields are often low because of the complexity of
animal host cells. Ultimately, the use of animal cells incurs higher costs, requires more time, and
may still result in low yield protein expression.
Yeast Systems. Yeast species such as Saccharomyces cerevisiae, Pichia pastoris, and
Kluyveromyces lactis provide many of the advantages of both bacterial and animal expression
systems while eliminating many drawbacks because they are single-cell fungi. Yeast genetics
are well-characterized and easily manipulated. E. coli retain their recombinant genetic
programming as plasmids that can be lost with time and lack of selection pressure and stable
transformants of animal cells can be difficult to generate and screen. Many expression systems
for yeast, however, rely on homologous recombination to insert the new genes directly into the
host genome. This yields many stable transformants that grow rapidly and are easy to screen,
with almost no risk of the cells losing their programing over time. Yeasts grow rapidly in
suspension to high cell densities and require simple media formulations and environmental
conditions. They are also very well suited to large batch fermentations; furthermore, they often
yield milligrams or grams of protein per liter of fermentation broth, making them useful for
industrial scale production.
Yeasts contain machinery for co- and post-translational modifications that are often
required for proper expression of human proteins; furthermore, lack of inclusion body formation,
a problem with E. coli, results in high yield recovery of properly folded proteins without the need
for harsh resolubilizing and refolding procedures. Although some yeast strains are known to
hyperglycosylate recombinant proteins (Niles et al. 1998; van Oort et al. 2002; van Oort et al.
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2004; Lockhart et al. 2005; Pepeliaev et al. 2011), more recently engineered strains of P. pastoris
can express proteins with several specific types of mammalian glycosylation (Pichia
GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichia-glycoswitch.php). Through the use
of yeast secretion signals like α-mating factor, recombinant proteins can be directed for secretion
into the growth media; consequently, this can eliminate the need for cell lysis.

P. pastoris and K. lactis as Recombinant Expression Systems
Recombinant expression systems based on the yeast species P. pastoris and K. lactis have
become well established and new improvements continue to emerge. Many expression plasmids
have been developed that apply various strategies to enable successful expression in both
species. Genetic programs available in these plasmids include options for inducible or
constitutive promoters, amino- (N-) and carboxyl (C-) terminal fusion tags, multiple reading
frames, and secreted or internal expression. Existing plasmids can, furthermore, be modified
through standard molecular cloning procedures to completely customize any aspect of the vector.
Homologous recombination is generally exploited to insert copies of linearized plasmid DNA,
called insertion cassettes, into the host genome. This creates a permanent stable transformation
of the cells into a new strain that expresses the recombinant protein construct of interest.
P. pastoris Expression System. Plasmids frequently used for expression in the
methylotrophic yeast P. pastoris include variants of the pPIC family (Life Technologies) that use
the yeast’s methanol-inducible AOX1 gene transcriptional promoter. This promoter provides
tight regulation of recombinant protein expression based on the choice of carbon source because
it is repressed by glucose and glycerol and induced by methanol, which the yeast can metabolize
as the sole carbon source; furthermore, such strong control of induction can benefit the

21

expression of toxic proteins. Clones containing multiple repeat tandem copies of the insertion
cassette occur with high frequency and can improve protein expression levels.
The pPICzα plasmids encode the secretion signal propeptide sequence for yeast α-mating
factor that directs recombinant proteins for secretion into the growth medium, whereas pPICz
plasmids lack this sequence and result in intracellular protein accumulation. The α-mating factor
propeptide is removed from the N-terminus during secretion by including the sequence of a
cleavage target site for the furin-like protease kexin, resulting in production of recombinant
protein with a native N-terminus that is present in the culture supernatant.
The pPICz and pPICzα plasmids contain a gene for resistance to the antibiotic Zeocin
(Life Technologies) that enables selection of transformed P. pastoris and E. coli. Zeocin
selection produces virtually no background of untransformed clones and serves to prevent later
contamination of transformant stocks with untransformed cells.
K. lactis Expression System. The plasmid pKLAC1 (New England Biolabs) is designed
for homologous recombination of multiple repeat tandem copies of the cassette into the genome
of K. lactis under control of the galactose-inducible LAC4 promoter, also repressed by glucose
and glycerol. Galactose has the advantage of being nonflammable, unlike the methanol used for
induction of AOX1. As with pPICzα, pKLAC1 encodes the yeast α-mating factor signal
propeptide sequence that is removed by kexin in the Golgi apparatus and results in secretion of
mature proteins with native N-termini.
To isolate transformants, pKLAC1 uses ampicillin antibiotic resistance selection for E.
coli and acetamide metabolism selection for K. lactis (Read et al. 2007). The plasmid transforms
K. lactis to express the enzyme acetamidase that is required for the metabolism of acetamide as a
nitrogen source; consequently, plating on nitrogen-free, yeast carbon base (YCB) agar containing
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acetamide selects for growth of transformed clones. This selection process improves the
selection of multicopy transformants; however, it can generate a background of colonies that
slowly metabolize acetamide and can be difficult to distinguish from true transformants.

Custom Tailored Gene Synthesis and Codon Usage Optimization
Traditional methods for cloning typically use reverse transcription polymerase chain
reaction (RT-PCR) to create and amplify complementary DNA (cDNA) copies of a naturally
occurring, intron-free, mRNA that encodes the protein of interest. PCR primers can be designed
to incorporate suitable restriction endonuclease cleavage sites that then facilitate cloning into a
chosen vector. In contrast to this approach, custom gene synthesis has many advantages that
simplify the cloning process, enhance the malleability of the gene and protein sequences, and
improve expression levels of recombinant proteins. Commercially synthesized genes of any
nucleotide sequence can be customized with any features such as restriction endonuclease
recognition sequences for molecular cloning into vectors; similarly, undesirable restriction
endonuclease sites and mRNA secondary structure can be eliminated from the sequence through
the use of alternative codons. Custom synthesis facilitates the engineering of multiple-domain
fusion proteins, especially those whose component sequences deviate significantly from their
naturally occurring mRNA counterparts.
Because not all species express the same levels of the same tRNAs, different organisms
translate individual codons with varying efficiencies. This phenomenon of codon usage
preference can have considerable impact on protein production in foreign hosts because the
codons most prevalent in the recombinant gene may not correspond to the codons used most
efficiently by the expression system. This can cause ribosomal stalling and disassembly that
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result in incomplete, partially translated proteins and a reduction in the efficiency of protein
production.
DNA sequence databases have been analyzed extensively to determine the statistical
frequencies with which codons occur within the total population of characterized protein-coding
genes for many species (Nakamura et al. 2000). These data are available publicly
(http://www.kazusa.or.jp/codon/) (Nakamura et al. 2000) and an internet website
(http://gcua.schoedl.de/index.html) (Fuhrmann et al. 2004) facilitates comparisons of codon
usage for gene sequences between organisms.
A comparison of the codon usage tables for the relative frequencies (RFs) of several
amino acids in Homo sapiens, P. pastoris, and K. lactis reveals some important differences
(Figure 1.1). For example, among the 6 available codons for the amino acid Arg, the codons
AGA, AGG, CGC, and CGG each appear approximately 20% of the time in human genes
(Figure 1.1a); however, the codon AGA is used in 48% and 51% of total Arg codon occurrences
in P. pastoris and K. lactis, respectively, (Figure 1.1b). Also, the sequences CGC and CGG each
only occur as 5% of the Arg codons in P. pastoris and K. lactis although they appear more
frequently in human genes. Gln provides another good example in that the codon CAG is
preferred, with RF = 73%, in human genes, whereas CAA is the preferred codon, with RF = 61%
and 67% in P. pastoris and K. lactis, respectively. Frequency of codon occurrence may correlate
with protein translation efficiency; however, data are lacking that directly characterize the
relative frequencies of tRNA expression in different organisms.
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Figure 1.1: Codon Usage Frequency. Partial comparison shows differences in relative codon
usage frequencies between H. sapiens (blue), P. pastoris (black), and K. lactis (red). Data
represent the relative frequency (RF) as a percentage of total codon occurrences for the given
amino acid in the genome of the species indicated. A. H. sapiens and P. pastoris. B. K. lactis
and P. pastoris. Images adapted from http://gcua.schoedl.de/index.html.

Custom DNA synthesis facilitates the optimization of codon usage within a recombinant
gene to match the codon preferences of the protein expression system (Figure 1.2). For example,
Figure 1.2 shows a codon optimization of the first 50 residues of active human neutrophil
elastase (HNE) for P. pastoris codon usage frequency tables. Figure 1.2a shows the native
human cDNA sequence, by codon, along with the relative adaptiveness (RA) of that codon for
expression in P. pastoris. Unlike the RF (Figure 1.1), the RA designates a value of 100% for the
most frequently used codon for a given amino acid and the RA values for the other analogous
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codons are presented as a percentage of the most frequently used codon. The RA measurement
scale is preferred over RF for comparing cDNA sequences because it facilitates rapid visual
interpretation of the data.

Figure 1.2: Codon Optimization. Codon usage analysis is shown for expression in P. pastoris
based on relative adaptiveness (RA). The codons are shown for the amino acids Ile16-Ala66 of
(A) Native HNE cDNA and (B) Recombinant HNE cDNA that is codon optimized for P.
pastoris. RA represents the percentage of codon usage relative to the codon most frequently
used for the given amino acid by P. pastoris. Codons of low occurrence with RA >15% appear
in gray and those with RA >10% appear in red (A). Codon optimization replaces these codons
with sequences more prevalent in the target genome (B). Images adapted from
http://gcua.schoedl.de/index.html.

Figure 1.2a shows that the codons used in the native human cDNA are not the codons
most preferred by P. pastoris, especially in the cases of 4 Arg residues with RA = 10% and six
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Ala residues with RA = 13%. A synthetic cDNA for the same amino acid sequence codonoptimized for expression in P. pastoris (Figure 1.2b) incorporates codons with much higher RF
in the yeast that results in higher RA values in the cDNA. The most preferred codon is not
always chosen, however, in order to avoid mRNA self-complementarity that forms stable
secondary structures, intron splicing sites, and unwanted internal restriction sites. This process
of codon optimization can have robust positive effects on expression levels, although such
effects are not always experienced.

Designing Recombinant Proteins
Recombinant protein expression technologies facilitate endeavors in protein
experimentation and design. Amino acid substitutions by site directed mutagenesis are useful for
studying the contributions of individual residues to the overall structural and functional
characteristics of a given protein. Fusion proteins can be created by linking multiple distinct
protein domains to combine their individual properties into a single molecular chimera, a process
whose benefits are limited only by the folding and functionality of the selected domains. Amino
acid sequences with known molecular recognition and binding properties can be exploited to
affect the functionality of the product.
Amino Acid Substitutions and Deletions. Custom gene synthesis and site-directed
mutagenesis can be used to selectively replace individual amino acid residues within a
recombinant protein. Such substitutions prove advantageous in recombinant protein expression
for many reasons. Residues with key roles in enzyme specificity, activity, and other functions
can be manipulated individually to determine the effects of their replacement and alter the
behaviors of proteins. Similarly, entire regions of native proteins can be deleted to evaluate their
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contributions to processes such as protein trafficking, DNA and RNA binding, signaling, and
enzymatic activity. Although alterations of amino acid sequence can have unintended
consequences, even these results can provide insights into the roles of individual residues in
protein behavior.
It has been shown that many proteins of high isoelectric point (pI) do not express well in
the yeast P. pastoris (Boettner et al. 2007). Often, highly charged proteins are susceptible to
proteolysis due to the high content of arginine and lysine residues, which can be substrates for
many proteases. Of particular concern for secreted expression in yeast, a high frequency of basic
residues increases the likelihood that the dibasic sequences RR~X and KR~X, substrates for the
yeast protease kexin, will occur that may lead to unwanted proteolysis during protein secretion.
These issues can be ameliorated by the selective substitution of amino acids to eliminate such
sites.
Known and potential sites of co- and post-translational modification can also be
manipulated or disrupted to evaluate their roles in normal biological processes. This can aid in
the evaluation of potential sites of glycosylation, phosphorylation, proteolysis, or other
modifications to determine how these processes affect the behavior of a protein. As previously
mentioned, many yeast species are prone to over glycosylate recombinant proteins (Niles et al.
1998 ; van Oort et al. 2002; van Oort et al. 2004; Lockhart et al. 2005; Pepeliaev et al. 2011);
furthermore, many biochemical studies require the enzymatic removal of glycosylation.
Conservative amino acid substitution to eliminate glycosylation sites can prevent these issues
and simplify research efforts.
Fusion Proteins and Tags. By combining sequences for different protein domains into a
single polypeptide chain, a fusion protein can be expressed that exhibits the properties of its
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individual, modular components. Several types of domains are frequently exploited to improve
the expression, detection, and purification of recombinant proteins. With some creativity, novel
approaches can also be engineered that take advantage of protein properties in other ways
through their inclusion in a fusion design.
As mentioned above, the yeast α-mating factor signal sequence is often exploited to
direct recombinant proteins for secretion by both P. pastoris and K. lactis and this can be used to
improve expression and recovery of recombinant proteins. Secreted proteins do not require cell
lysis prior to purification, nor are they as prone to rapid degradation as proteins expressed inside
the cell, although some extracellular proteases are produced. In E. coli, recombinant proteins
commonly accumulate as insoluble inclusion bodies that require harsh chemical treatments to
solubilize and refold, often resulting in poor yields; consequently, highly soluble proteins such as
thioredoxin, serum albumin, or small ubiquitin-like modifier (SUMO) protein are sometimes
tethered to desired recombinants in efforts to thwart inclusion body formation, thus improving
expression and recovery.
Numerous fusion domains are available to facilitate detection of recombinant proteins as
well. Several fluorogenic proteins based on the Aequorea victoria green fluorescent protein
(GFP) (Prasher et al. 1992; Chalfie et al. 1994; Inouye and Tsuji 1994) have been engineered that
exhibit fluorescent properties across a spectrum of colors including cyan (Heim and Tsien 1996;
Tsien 1998), blue (Heim et al. 1994; Heim and Tsien 1996), green (Yang et al. 1996; Tsien 1998;
Zapata-Hommer and Griesbeck 2003), and yellow (Ormö et al. 1996; Wachter et al. 1998).
Fluorescent proteins based on the red fluorescent protein of Discosoma species have also been
developed in a range of fluorescent colors spanning cyan to far-red (Matz et al. 1999; Campbell
et al. 2002; Shaner et al. 2004; Wang et al. 2004; Shaner et al. 2005; Shu et al. 2006; Shaner et
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al. 2007; Alieva et al. 2008; Shaner et al. 2008; Shaner 2013). Protein fluorescence is often used
to visualize protein localization and transport by fluorescence microscopy; furthermore, studies
of transcriptional promoters as well as protein-DNA and protein-protein interactions can be
facilitated through the use of fluorescent proteins as reporter genes for experiments in promoter
alteration or yeast two-hybridization.
Limited work has also been done regarding the use of chromogenic proteins as fusion
partners, although few such proteins are known. Rubredoxin, which binds iron, and the hemebinding protein cytochrome B5 (CytB5) both display a characteristic absorbance of light at 410
nm accompanied by a red coloration and have been used to detect the expression of their
recombinant fusions (Kohli and Ostermeier 2003; Finn et al. 2005; Mitra et al. 2005). With a
higher extinction coefficient at 410 nm, CytB5 provides a stronger, more easily detectable signal
than rubredoxin (Mitra et al. 2005). The flavin mononucleotide (FMN)-binding domain of
human cytochrome P450 reductase has also been used for its characteristic yellow color and
absorbance at 450 nm (Finn et al. 2005). While the detection of fluorescent proteins requires
specialized equipment, chromogenic proteins can be detected visually and by simple
spectrophotometry and this makes them useful for following recombinant protein expression and
purification.
Antibody epitope short peptide tags like the myc-tag (EQKLISEEDL), the FLAG® tag
(DYKDDDDK) (Sigma), and polyhistidine tags that can be added to the N- or C- terminus of a
protein see considerable use for detection and they can also be useful for purification.
Antibodies are available that recognize each of these sequences and this is especially useful for
Western blotting, ELISA, immunohistochemistry (IHC), and immunocytochemistry (ICC).
Myc-tag and FLAG® tag monoclonal antibodies can also be used to purify proteins by antibody
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affinity chromatography. Polyhistidine tags, most commonly the hexahistidine (6xHis) tag, will
bind divalent metal cations like Co2+, Cu2+, and Ni2+ by sharing electrons and this can be
exploited to purify polyhistidine tagged proteins by immobilized metal affinity chromatography
(IMAC) (Hochuli 1988).
Designing Internal Proteolytic Sites. Because many recombinant fusion proteins require
the separation of fusion partners by proteolysis for proper function or further study, proteolytic
sites can be incorporated; however, few proteases possess the high level of substrate specificity
required to prevent unintended proteolytic events. Among the most commonly used proteases
for this purpose are coagulation factor Xa, thrombin, tobacco etch virus (TEV) protease, and
enteropeptidase. The commonly used thrombin cleavage site is LVPR~GS and the usual TEV
protease cleavage sites are ENLYFQ~G and ENLYFQ~S (where “~” represents the cleavage
site); however, these approaches leave G or S (TEV protease) or GS (thrombin) at the Nterminus of the C-terminal domain, which can be problematic, especially for the activation of
enzymes, such as serine proteases, whose functions require an exposed native N-terminus.
Factor Xa, which turns prothrombin into active thrombin and prefers the sequences
IEGR~X and IDGR~X (where X can be any amino acid other than proline), and enteropeptidase
(EP, originally called enterokinase), which converts inactive trypsinogen into active trypsin and
prefers the sequences DDDDK~X (LaVallie et al. 1993; Lu et al. 1997) and DDDDR~X
substrates (Mikhailova et al. 2007; Gasparian et al. 2011; Smith and Johnson 2013), have been
nicknamed “restriction proteases” for their extreme substrate specificities, similar to the wellknown restriction endonucleases from which the moniker is derived. Unlike thrombin and TEV
protease, factor Xa and EP exhibit no preference for amino acids on the P’ side (nomenclature of
Schechter and Berger (Schechter and Berger 1967)) of the target peptide bond; consequently, the
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specificities of these 2 enzymes can be used to expose the native N-termini of proteins upon the
removal of fusion domains.
Although EP has high preference for the DDDDK~X (LaVallie et al. 1993; Lu et al.
1997) and DDDDR~X (Mikhailova et al. 2007; Gasparian et al. 2011) substrate sequences, this
protease will cleave other sequences with significantly lower specificity in the absence of a
sufficient concentration of the intended target enzyme (Light et al. 1980; Likhareva et al. 2002;
Liew et al. 2005; Shahravan et al. 2008; Chen et al. 2012). The enzyme’s preference comes from
charge-based attractions to the substrate. The positively charged Lys (K) or Arg (R) in the P1
position is drawn into the negatively charged S1 specificity pocket of EP; furthermore, the 4
negatively charged Asp (D) residues coordinate with positively charged, adjacent residues on the
enzyme surface. While EP from all species use a negatively charged Asp 189
(chymotrypsinogen numbering system) at the base of the S1 pocket, species-specific differences
in positive charge distribution in the S2 – S4 sites affect the extended substrate specificity. It is
possible to use recombinant protein engineering to create modified variants of EP that
manipulate this positive charge distribution to alter or improve the enzyme’s substrate specificity
(Chun et al. 2011; Ostapchenko et al. 2012; Smith and Johnson 2013).
Chapter 2 presents the recombinant expression of 2 variants of the light chain of human
EP with modified substrate specificities. Both variants were secreted by P. pastoris as functional
enzymes and purified to homogeneity. One variant, R96Q, reduced the specificity of EP for the
extended substrates DDDDK~X and DDDDR~X by reducing the amount of positive charge in
the extended binding pocket. The other EP substitution variant, Y174R, improved the enzyme’s
specificity significantly for both substrates through the addition of positive charge to improve
charge based interactions between the substrates and the extended binding site.
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Serine Proteases
Enteropeptidase, factor Xa, and thrombin are members of the chymotrypsin-like S1 clan
of serine proteases, characterized by the high similarity of their tertiary structures and by their
identical active site architecture. All serine proteases are related through the use of an electron
relay mechanism that activates a nucleophilic oxygen atom on the side chain of the eponymous
serine residue in the active site. Among the chymotrypsin-like serine proteases, the active site
consists of 3 residues: His 57, Asp 102, and Ser 195 (chymotrypsinogen numbering system)
(Ressler 1985; Craik et al. 1987; Sprang et al. 1987; Carter and Wells 1988; Polgár 2005;
Fuhrmann et al. 2006) that are arranged so that His 57, stabilized by Asp 102, withdraws the H+
atom from the side chain oxygen of Ser 195. The topology and charge distribution of the
substrate binding grooves of serine proteases position selected protein substrates so that the
activated serine nucleophile attacks the carbonyl carbon of a target peptide bond to form a
tetrahedral intermediate that then undergoes hydrolysis as the enzyme catalyst releases the
resulting product fragments and returns to its original nucleophile form.
The roles of serine proteases in numerous biological processes and diseases emphasize
their importance in biomedical research. Blood coagulation is initiated by an activation cascade
of either 3 (extrinsic pathway) or 6 (intrinsic pathway) serine proteases, resulting in the
generation of active thrombin that converts inert fibrinogen into clot-forming fibrin (Davie and
Ratnoff 1964; MacFarlane 1964); furthermore, disruptions in this protease activation cascade
cause hemophilia. In the duodenum (Hermon-Taylor et al. 1977), enteropeptidase converts
trypsinogen into active trypsin, a serine protease with broad specificity for positively charged P1
residues (Schechter-Berger nomenclature) (Schechter and Berger 1967). This initiates a cascade
of digestive enzyme activation including the three archetypal S1 clan serine proteases: trypsin,
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chymotrypsin, and pancreatic elastase. These 3 proteases digest proteins into single amino acids
and dipeptides for intestinal absorption. Deficiencies in enteropeptidase (Haworth et al. 1971;
Hadorn et al. 1975) and trypsin (Townes 1965) lead to digestive disorders with symptoms
including intestinal malabsorption, hypoproteinemia, and growth failure. These are only 2
examples of the innumerable functions of serine proteases in human physiology and disease.

Neutrophil Serine Proteases of Primary (Azurophil) Granules
Neutrophils are the most abundant type of white blood cell and the human body’s first
line of defense against invasion by pathogenic bacteria and fungi (Borregaard and Cowland
1997; Borregaard et al. 2005). Also known as polymorphonuclear (PMN) leukocytes,
neutrophils engulf and destroy infiltrators by phagocytosis, at which time primary (azurophil)
granules fuse with the phagolysosome and release their cytotoxic contents upon the pathogen.
The primary granules of neutrophils store large amounts of the enzyme myeloperoxidase (MPO)
and the chymotrypsin-like neutrophil serine proteases (NSPs) cathepsin G (CatG), human
neutrophil elastase (HNE), and proteinase 3 (Pr3, also called myeloblastin), in addition to several
other antimicrobial proteins (Faurschou and Borregaard 2003; Garwicz et al. 2005; Pham 2006).
While the oxidative stress of MPO-derived hypochlorous acid was originally considered
the primary means of microbial killing, research has since shown that NSPs of the azurophil
granules play important, nonredundant roles in neutrophil lethality (Belaaouaj et al. 1998;
Belaaouaj et al. 2000; Tkalcevic et al. 2000; Belaaouaj 2002; Reeves et al. 2002; Hirche et al.
2004; López-Boado et al. 2004; Urban et al. 2006); furthermore, the killing functions of these
NSPs are not limited to their proteolytic activity, but also a result of abundant positively charged
residues. Antimicrobial peptides of strong positive charge are released by the degradation of
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NSPs and both the positively charged enzymes and peptides can associate with the negatively
charged surfaces of microorganisms and exert cytotoxic effects independent of proteolytic
activity (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991; Miyasaki et al. 1993;
Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002; Korkmaz et al. 2010). In a recently
discovered extracellular killing mechanism, the neutrophil extracellular trap (NET), neutrophils
also release a network of enzyme-laden chromatin to ensnare and destroy microbes in the
extracellular milieu (Brinkmann et al. 2004; Urban et al. 2006; Wartha et al. 2007;
Papayannopoulos et al. 2010; Amulic and Hayes 2011).
CatG, HNE, and Pr3 not only function to directly destroy pathogens but also to affect the
inflammatory response through signaling pathways. These enzymes process cytokines (Scuderi
et al. 1991; Bank et al. 1999; Benabid et al. 2012), chemokines (Padrines et al. 1994; Nufer et al.
1999; Rao et al. 2004; Berahovich et al. 2005; Ryu et al. 2005; Wittamer et al. 2005), and
protease activated receptors (PARs) (Sambrano et al. 2000; Cumashi et al. 2001) with both
proinflammatory and antiinflammatory consequences (Pham 2006; Korkmaz et al. 2008;
Korkmaz et al. 2010). Although Pr3 and CatG cleave chemokines that promote monocyte
chemotaxis (Padrines et al. 1994; Nufer et al. 1999; Berahovich et al. 2005) and HNE and CatG
action can cause recruitment of antigen-presenting macrophages and dendritic cells (Wittamer et
al. 2005), the net effects of NSPs on inflammation and immune cell recruitment remain unclear
because these enzymes also process several antiinflammatory chemokines and cytokines as well.
For example, both CatG and HNE inactivate TNFα (Scuderi et al. 1991), whereas Pr3 activates
this proinflammatory cytokine (Robache-Gallea et al. 1995); however, CatG, HNE, and Pr3 all
inactivate the proinflammatory cytokine IL-6 (Bank et al. 1999).
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The NSPs of azurophil granules have also been implicated in several human diseases
associated with inflammation and tissue destruction (Korkmaz et al. 2008; Korkmaz et al. 2010).
These enzymes have strong proteolytic activities and are present in abundance at sites of
inflammation; furthermore, they can destroy host tissues if improperly regulated. They can all
cleave collagens, elastin, fibronectin, laminin, and proteoglycans (Starkey 1977; Pipoly and
Crouch 1987; Rao et al. 1991; Korkmaz et al. 2008), making them particularly damaging to
extracellular matrices and connective tissues, especially in inflammatory lung diseases like acute
lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disorder
(COPD), cystic fibrosis, and emphysema (Lee and Downey 2001a; 2001b; Shapiro 2002; Moraes
et al. 2003; Shapiro et al. 2003; Moraes et al. 2006; Korkmaz et al. 2008; Owen 2008; Korkmaz
et al. 2010).
CatG, HNE, and Pr3 are all synthesized in the promyelocytic stage of early neutrophil
maturation as inactive preproproteins and directed to the primary granules (Gullberg et al. 1997;
Garwicz et al. 1998; Garwicz et al. 2005). Although the key component of NSP sorting into
these granules is the timing of their biosynthesis, the molecular means by which the enzymes are
directed to their eventual destinations is unclear (Korkmaz et al. 2008; Korkmaz et al. 2010). All
3 inactive proteins contain N-terminal leader sequences that direct them into the rough
endoplasmic reticulum and are removed during posttranslational processing (Salvesen and
Enghild 1991; McGuire et al. 1993; Sköld et al. 2002; Korkmaz et al. 2008). The resulting NSP
zymogens contain N-terminal prodipeptides that are removed by dipeptidyl peptidase I (DPP I,
also called Cathepsin C) inside the granules to expose the native N-terminal Ile 16, required for
the activity of all chymotrypsin-like serine proteases (Salvesen and Enghild 1991; McGuire et al.
1993; Sköld et al. 2002; Korkmaz et al. 2008).

36

In addition to this type of zymogen activation, which is common to all members of the S1
clan, CatG, HNE, and Pr3 also contain unusual C-terminal propeptide extensions (“tails”) of
varying lengths and sequences (Gullberg et al. 1995; Gullberg et al. 1997; Capizzi et al. 2003).
In an evolutionarily conserved process, these C-terminal tails are removed by an unidentified
protease (or proteases); furthermore, the tails are dissimilar and have no known functions. They
do not appear to affect the activities of the enzymes, nor are they required for correct
intracellular trafficking (Gullberg et al. 1995; Källquist et al. 2010; Korkmaz et al. 2010). An
amino acid sequence alignment of CatG, HNE, and Pr3 (Figure 3.1) shows the relative positions
of Ile 16, His 57, Asp 102, Ser 195, and the C-terminal extensions.

Figure 1.3: NSP Sequence Alignment. Native sequences for human CatG, HNE, and Pr3 are
aligned, illustrating similarities and differences. All residues required for catalytic activity
appear in green. The N-terminal Ile 16 ( ) must be exposed for catalytic activity. The residues
that comprise the catalytic triad ( ) include His 57, Asp 102, and Ser 195. C-terminal
propeptide extensions appear in bold with red underline.
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Human Proteinase 3. Pr3 can be found not only in the primary granules and in NETs but
also in secondary (specific) granules, secretory vesicles, and in association with the neutrophil
cell surface (Korkmaz et al. 2008; Korkmaz et al. 2010). This serine protease demonstrates a
preference for short hydrophobic amino acid residues, especially Val, Ala, and Thr, in the P1
position; furthermore, endogenous inhibitors of Pr3 include α2-macroglobulin, α1-antitrypsin
(α1-AT, also called α1-proteinase inhibitor), and elafin (Korkmaz et al. 2008; Korkmaz et al.
2010). Mature Pr3 contains 222 amino acids (Campanelli et al. 1990), has an isoelectric point
(pI) of ~9.5 and it bears a positive charge at physiologically relevant pH due to its high content
of arginine (13 residues); consequently, Pr3 has bactericidal properties independent of its
proteolytic function, as do HNE and CatG (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al.
1991; Miyasaki et al. 1993; Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002; Korkmaz et
al. 2010). The C-terminal tail of Pr3, 8 amino acids in length, is the shortest among the azurophil
granule NSPs and little is known about its function (Capizzi et al. 2003).
Antineutrophil cytoplasmic antibodies (ANCAs) are responsible for several diseases
characterized by autoantibodies against neutrophils accompanied by blood vessel inflammation.
Pr3 is the main antigen recognized by cytoplasmic ANCAs (cANCAs) and this phenomenon
corresponds with the relatively uncommon disease Wegener’s Granulomatosis (WG), for which
the cause is not fully understood (Campanelli et al. 1990; Rao et al. 1991; Specks et al. 1997;
Capizzi et al. 2003; Caughey 2006; Korkmaz et al. 2010). The primary symptoms of WG are
vasculitis and necrotizing, granulomatous inflammation of small blood vessels (Fauci and Wolff
1973; Sarraf and Sneller 2005); furthermore, it affects approximately 1 in 20,000 people, most
between 40 – 60 years of age (Cotch et al. 1996). Secondary symptoms can include cold or
sinusitis that is not cured by normal means, inflammation of the ears or eyes, nasal membrane
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crusting and ulceration, or saddle-nose deformity (Fauci and Wolff 1973; Sarraf and Sneller
2005; Korkmaz et al. 2010). According to the National Institute of Allergy and Infectious
Disease, WG is typically treated with glucocorticoids and cytotoxic compounds
(http://www.niaid.nih.gov/topics/wegeners/pages/treatment.aspx).
Human Neutrophil Elastase. HNE shares 54% sequence identity with Pr3; however,
unlike Pr3, HNE is localized in NETs and the azurophil granules but not in other granules or
vesicles, although some HNE is also associated with the neutrophil cell surface and in the
nucleus (Pham 2006; Korkmaz et al. 2008; Korkmaz et al. 2010). Similar to Pr3, HNE also
prefers small hydrophobic residues at the P1 position, especially Val, Ile, Thr, Ala, and Leu
(Bode et al. 1986). Still, HNE and Pr3 do not share extended substrate specificity for residues in
other positions; consequently, they process different proteins and play separate roles in
neutrophil function. Mature HNE contains 218 amino acids (Bode et al. 1986; Sinha et al. 1987)
and has a pI of ~10.8, making it more positively charged than Pr3 under physiological
conditions. This strong positive charge results from 19 arginine residues and also gives HNE
antibacterial properties independent of catalytic activity (Korkmaz et al. 2010). HNE is inhibited
physiologically by the same inhibitors as PR3: α2-macroglobulin, α1-AT, and elafin; however,
HNE is also inhibited by secretory leukocyte proteinase inhibitor (SLPI), which does not inhibit
Pr3 (Korkmaz et al. 2008; Korkmaz et al. 2010).
The C-terminal tail of HNE is 20 amino acids long, the longest among the 3 azurophil
granule NSPs; furthermore, it has been studied more extensively that the tails of Pr3 or CatG
because of its potential role in severe congenital neutropenia (SCN), discussed below. Although
the C-terminal extension is not required for the granular localization of HNE, the presence of the
tail does direct at least a portion of HNE to the cell membrane prior to reuptake of the enzyme by
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endocytosis (Tapper et al. 2006); furthermore, blocking the tail of HNE with a fusion extension
prevents this reuptake (Källquist et al. 2010). Trafficking of Pr3 does not occur in the same
manner (Källquist et al. 2010). The removal of the C-terminal tail exposes a recognition site for
the µ3a subunit of the adaptor protein 3 (AP3) complex (Benson et al. 2003). It was previously
suggested that the µ3a subunit may bind HNE at this site to direct granular localization (Benson
et al. 2003); however, a more recent model suggests that the tetraspanin CD63 associates with
HNE to mediate AP3-dependent trafficking (Källquist et al. 2008).
Cyclic neutropenia (CN, also called cyclic hematopoiesis), and SCN are diseases of
neutrophil maturation caused primarily by mutations in the HNE gene, ELANE (Horwitz et al.
1999; Dale et al. 2000; Li and Horwitz 2001; Benson et al. 2003; Horwitz et al. 2004; Horwitz et
al. 2007; Korkmaz et al. 2010; Horwitz et al. 2013). CN is characterized by neutrophil counts
that oscillate between normal and almost zero with a 21-day cycling time (Krance et al. 1982;
Lange 1983). In a genomic study of 13 families with a history CN, 7 heterozygous mutations of
ELANE are found in all cases (Horwitz et al. 1999). SCN is a disease of neutrophil maturation
arrest, with symptoms including chronic low circulating neutrophil counts, structurally abnormal
neutrophils with functional deficiencies, and increased susceptibility to infections (Kostmann
1956; 1975; Carlsson and Fasth 2001; Horwitz et al. 2003; Horwitz et al. 2007;). Although other
gene mutations have been implicated in some, 21 out of 27 independent cases of SCN show 1 of
15 different heterozygous mutations of ELANE (that sometimes also overlap with mutations that
cause CN) (Dale et al. 2000). All chain-terminating mutations of ELANE that result in
production of C-terminally truncated HNE, which accompany many cases of SCN but not CN,
occur in the fifth (final) exon (Benson et al. 2003; Horwitz et al. 2013).

40

Two hypotheses have been proposed for how HNE can cause CN and SCN. The
mislocalization hypothesis is based on canine cyclic neutropenia, or gray collie syndrome, in
which mutations of the beta subunit of AP3 lead to mislocalization of HNE (Benson et al. 2003);
however, the human disease most analogous to canine cyclic neutropenia is Hermansky-Pudlak
syndrome and not CN or SCN (Horwitz et al. 2013). The second hypothesis suggests that the
offending ELANE mutations cause misfolding of HNE and induction of an unfolded protein
response that leads to neutrophil apoptosis (Köllner et al. 2006). Several neutropenia-causing
mutations of ELANE lead to the cytoplasmic accumulation of unfolded HNE causing apoptosis
in transformed U937 cells (Köllner et al. 2006).
Human Cathepsin G. CatG appears only in the azurophil granules, on the neutrophil cell
surface, and in NETs (Pham 2006; Korkmaz et al. 2008; Korkmaz et al. 2010). The broad,
hydrophobic S1 binding pocket of CatG confers a chymotrypsin-like P1 specificity for the
hydrophobic aromatic amino acid residues Tyr and Phe; however, a positively charged Glu 226
side chain resides at the base of the specificity pocket that also gives CatG trypsin-like P1
specificity for the positively charged amino acids Lys and Arg (Tanaka et al. 1985; Hof et al.
1996). This dual specificity is unusual among serine proteases and warrants further biochemical
research. Mature CatG has an uncommonly high pI of ~12.0 because this protein, 224 amino
acids in length (Salvesen et al. 1987; Hof et al. 1996), contains 34 Arg residues, 15.2 % of its
total amino acid content. Proteolytically inactive CatG and synthetic peptides derived from
positively charged portions of the CatG amino acid sequence have strong antimicrobial
properties (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991; Miyasaki et al. 1993;
Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002). CatG is endogenously inhibited by α2-
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macroglobulin, α1-AT, α1-antichymotrypsin, and SLPI, but not elafin, which inhibits HNE and
Pr3 (Korkmaz et al. 2008; Korkmaz et al. 2010).
The C-terminal tail of CatG is 11 – 13 amino acids long and the exact site of its removal
is unclear. Among the available crystallographic models of mature native CatG, 3 show the
presence of Ser 244 at the C-terminus (PDB ID: 1CGH, 1AU8, and 1T32) while 1 ends at Arg
243 (PDB ID: 1KYN) (Hof et al. 1996; Greco et al. 2002; de Garavilla et al. 2005). It is possible
that CatG may remove its own tail by limited autolysis at Arg 243; however, CatG cannot
remove the tail by cleaving at Ser 244, which appears to be the more common cleavage site.
Expression of Recombinant Human NSPs. Recombinant human Pr3 has been expressed
successfully in several animal cell lines including: U937 cells (Rao et al. 1996; Dublet et al.
2005), Sf9 insect cells (Jenne and Kuhl 2006), RBL cells (Pederzoli et al. 2005), HMC-1 cells
(Pederzoli et al. 2005; Jenne and Kuhl 2006), HEK239 cells (Jenne and Kuhl 2006), and COS
cells (Källquist et al. 2010). Much of this work has been spurred by the role of Pr3 as the key
autoantigen in Wegener’s Granulomatosis (see above). By contrast, HNE has been expressed
only in COS cells (Okano et al. 1990; Källquist et al. 2008; Källquist et al. 2010) and in RBL-1
cells (Gullberg et al. 1995; Tapper et al. 2006; Averhoff et al. 2008). For CatG, the recombinant
human enzyme has only been expressed in RBL cells or the murine myeloid cell line 32D
(Gullberg et al. 1994; Garwicz et al. 1995; Gullberg et al. 1995), while mouse CatG (lacking
trypsin-like substrate affinity found in primate and human CatG) and “humanized” mouse CatG
(with the mutation A226E that bestows the trypsin-like substrate affinity) have been expressed in
adherent Sf9 insect cells (Raymond et al. 2010).
While recombinant expression in mammalian cells has provided much information
regarding azurophil granule NSPs, these systems do not produce large (milligram-to-gram)
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quantities of protein efficiently, making them impractical for many in vitro biochemical studies.
Active, full-length human Pr3, including the C-terminal tail with an added 6xHis tag for
purification, was previously expressed in P. pastoris as a secreted protein with a yield of ~17
mg/L (Harmsen et al. 1997); however, similar attempts with HNE only generated 100 µg/L of
active enzyme and, separately, 1 mg/L of an enzymatically inactive H57A mutant, with low (5%)
recovery yields (Dall'Acqua et al. 1999). Cathepsin G has never been expressed as an active
enzyme in any unicellular microorganism and the need persists for robust expression platforms
for recombinant HNE and CatG.
Chapter 3 shows the successful expression and partial purification of recombinant HNE
and human CatG, both with intact C-terminal tails, by secretion using P. pastoris and the AOX1
methanol-inducible promoter. Expression of HNE in K. lactis, with limited success, is also
reported. Both enzymes are produced as inactive protease zymogens with an N-terminal fusion
domain connected by the EP cleavage site DDDDK~I; furthermore, these fusion proteins exhibit
proteolytic activities after treatment with EP to expose their native Ile 16 N-termini. The fusion
partner linked to each of these enzymes is the soluble heme-binding domain of the red
chromogenic protein cytochrome B5 (CytB5) with an N-terminal 6xHis tag for detection and
purification. Expression levels of active HNE in P. pastoris are improved 10 – 35 times
compared to the previous attempts of others (Dall'Acqua et al. 1999), likely by producing an
activable zymogen rather than the potentially toxic active enzyme. Although less than 200 µg of
active human CatG was expressed per liter of P. pastoris fermentation broth, this is the first
reported successful recombinant expression of active human CatG using cells that grow in
suspension in minimal growth medium to high culture density. The results of this study suggest
that the expression levels of HNE and human CatG in P. pastoris, as well as their purification,
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can be improved with further efforts and that this yeast makes a suitable platform for the
expression of useful quantities of modified NSPs.

C-Reactive Protein
Human C-reactive protein (CRP) is a positive acute-phase reactant produced by
hepatocytes and the circulating concentration of CRP in the bloodstream increases significantly
in response to upregulation of cytokine interleukin-6 (IL-6) as part of the nonspecific acutephase response (Pepys and Hirschfield 2003; Black et al. 2004). Discovered in 1930 and named
for its ability to precipitate C-lipopolysaccharide (Tillett and Francis 1930), which is a bacterial
endotoxin of the polysaccharide capsule of Streptococcus pneumonia, CRP binds
phosphocholine (PCh) that is exposed on the surface of pathogenic bacteria and damaged host
cells. The plasma half-life of CRP is about 19 hours (Vigushin et al. 1993); furthermore, longterm elevated levels of CRP reflect an increased risk of atherosclerosis (Chang et al. 2002;
Venugopal et al. 2002; Danenberg et al. 2003; Jialal et al. 2004; Paul et al. 2004; Agrawal et al.
2010), cardiovascular disease (Verma and Yeh 2003; Clearfield 2005; Yaron et al. 2006; YosefLevi et al. 2007), and diabetes (Pradhan et al. 2001; Dehghan et al. 2007). The American Heart
Association and the Centers for Disease Control and Prevention recommend its use as a clinical
marker for inflammation and for cardiovascular disease (Kimberly et al. 2003; Pearson et al.
2003; Kilpatrick and Bunk 2009).
Soluble, globular CRP monomers (Figure 1.4) associate via electrostatic interactions into
a pentamer (Figure 1.5) with a planar pentagonal quaternary ring structure and a central pore;
furthermore, this makes CRP a member of the pentraxin family of acute phase pattern
recognition receptors. The CRP pentamer has 2 opposing faces of distinct function. The
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recognition face (Figure 1.5a) binds PCh in a Ca2+ dependent manner and each of the 5 subunits
contains binding sites for 2 Ca2+ ions that complete another binding site by conferring high
affinity for the negative head group of 1 PCh molecule (Thompson et al. 1999). Other possible
ligands include chromatin, fibronectin, histones, laminin, phosphoethanolamine, ribonuclear
proteins, oxidized LDL (oxLDL) and the oxLDL receptor LOX-1 (Szalai et al. 1999; Black et al.
2003; Fujita et al. 2009; Shih et al. 2009; Singh et al. 2012). The globular head of C1q, a
complement component, binds to the central pore of CRP on the effector face (Figure 1.5b)
(Gaboriaud et al. 2003).

Figure 1.4: CRP Monomer. The tertiary backbone structure of the globular CRP monomer is
shown from (A) the recognition face or (B) a side view. On the backbone ribbon, beta sheet
structures appear in aquamarine and alpha helices appear in red. Ca2+ ions and PCh molecules
appear as space-filling models colored by atom where calcium = green, carbon = gray, nitrogen =
blue (obscured), phosphate = orange, and oxygen = red. Images were generated with Accelrys
Discovery Studio 3.1 using the crystal structure of pentameric CRP (PDB ID: 1B09).
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Figure 1.5: CRP Pentamer. The pentameric form of CRP is shown from (A) the recognition
face and (B) the effector face. Backbone ribbon structures appear inside space-filling models
that illustrate the distribution of charge, where positive charge appears in blue and negative
charge appears in red. Ca2+ ions appear in yellow and PCh molecules appear in green, with the
phosphate head groups of PCh oriented toward the Ca2+ ions. Images were generated with
Accelrys Discovery Studio 3.1 using the crystal structure of pentameric CRP (PDB ID: 1B09).

Pentameric CRP forms 2-dimensional arrays bound to PCh on the cell surface and these
arrays bind the globular head domains of C1q in a fashion similar to C1q cross-linking to Fc
domains of immune complexes; furthermore, C1q cross-linking with either Fc or CRP can
activate the complement cascade. CRP-mediated C1q recruitment and complement activation
depend only on the exposure of PCh instead of antigen recognition, although only complement
components C1-C4, but not C5-C9, are activated in response to CRP (Thompson et al. 1999;
Black et al. 2004). Complement components C1-C4 form the classical pathway of complement
activation and result in macrophage phagocytosis of opsonized target cells. Because CRP-
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mediated complement activation does not activate C5-C9, membrane attack complexes (MACs)
do not assemble or cause target cell lysis.
CRP has other immune-related functions in addition to the activation of complement,
with both pro- and anti-inflammatory results; however, the net in vivo effects of CRP on
inflammation are unclear and may be context dependent (Tilg et al. 1993; Heuertz et al. 1994;
Ahmed et al. 1996; Szalai et al. 1999; Mold et al. 2002; Black et al. 2004). CRP can be cleaved
by HNE into protein fragments that induce neutrophil apoptosis in vitro (Kakuta et al. 2006) and
this may help to limit neutrophil longevity and activity at sites of inflammation. Human CRP,
either administered or expressed in recombinant form, shows protective effects in experiments
using murine models of lung inflammatory diseases (modeled by induced alveolitis) (Heuertz et
al. 1994; Ahmed et al. 1996), multiple sclerosis (modeled by mouse allergic encephalomyelitis)
(Szalai et al. 2002), and systemic lupus erythematosus (SLE) (Du Clos et al. 1994; Szalai et al.
2003; Russell et al. 2004).
Much research suggests that CRP, which is known to localize in atherosclerotic lesions,
may have functions related to atherosclerosis; however, the net effects on lesion and plaque
formation are uncertain. While CRP does not normally bind native LDL (Chang et al. 2002;
Taskinen et al. 2002; van Tits et al. 2005), it has been shown, in vitro, to bind immobile
aggregates of LDL (de Beer et al. 1982; Fu and Borensztajn 2002; Agrawal et al. 2010) as well
as LDL that has been either enzymatically modified or chemically oxidized into
proatherosclerotic forms (Bhakdi et al. 1999; Agrawal et al. 2010; Chang et al. 2002). CRP
binds enzymatically modified LDL at neutral pH and this affinity increases with increasing
acidity (Bhakdi et al. 1999; Taskinen et al. 2002; Biró et al. 2007; Singh et al. 2008a).
Controversy exists regarding the affinity of CRP for oxidized LDL (oxLDL). While it has been
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shown that CRP binds oxLDL under acidic conditions (Singh et al. 2009) and some studies
demonstrate the same at physiological pH (Chang et al. 2002; van Tits et al. 2005), other work
indicates that CRP and oxLDL do not readily associate in a physiologically relevant environment
(Taskinen et al. 2002; Ji et al. 2006).
Some evidence indicates that CRP may opsonize LDL particles, resulting in the
phagocytosis of LDL by macrophages, which turns them into plaque-forming foam cells (Bhakdi
et al. 1999; Zwaka et al. 2001). Several other studies also support the hypothesis that CRP
enhances LDL uptake by macrophages and foam cell formation (Fu and Borensztajn 2002;
Verma et al. 2002; van Tits et al. 2005; Singh et al. 2008b). In other studies whose results
suggest that CRP may actually prevent foam cell formation, CRP-LDL complexes did not
convert macrophages into foam cells (Singh et al. 2008a) and the presence of CRP increased
LDL degradation by macrophages (Mookerjea et al. 1994). Unfortunately, the effects of CRP on
atherosclerosis have not been elucidated in vivo because CRP displays inconsistent effects on
disease progression in studies of animal models of atherosclerosis (Paul et al. 2004; Hirschfield
et al. 2005; Reifenberg et al. 2005; Schwedler et al. 2005; Trion et al. 2005; Tennent et al. 2008;
Torzewski et al. 2008; Agrawal et al. 2010).
It is proposed that increased acidity causes conformational changes in the CRP pentamer
that enable it to bind oxLDL and that this may have in vivo significance in the microenvironment
of atherosclerotic lesions (Singh et al. 2012). Similarly, researchers also suggest that the failure
of animal models of atherosclerosis to yield significant results in response to human CRP is due
to species-specific differences in this microenvironment (Singh et al. 2012). Recombinant CRP
E42Q, a single amino acid substitution variant, has been expressed in Chinese hamster ovary
(CHO) cells and found to bind oxLDL with improved affinity at higher pH, likely by increasing
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pentamer flexibility due to the disruption of the salt bridge between Glu 42 of each CRP subunit
and Lys 119 of the adjacent subunit (Singh et al. 2012). Because of the additional flexibility and
improved oxLDL affinity, the E42Q variant may provide a useful tool to overcome the current
issues with in vivo studies of the effects of CRP-LDL complex formation on atherosclerosis in
animal models. This could help determine the net effects of CRP on atherosclerotic progression.
If net protective roles against plaque formation are discovered, then recombinant CRP variants
may even have therapeutic value in the treatment of atherosclerosis.
Because CHO cells suffer from many of the drawbacks of other mammalian recombinant
expression platforms, production times and total yields of CRP E42Q may be insufficient to
provide enough protein for studies in animal models. By producing CRP and variants like CRP
E42Q in a recombinant protein expression system, larger quantities of these proteins may be
generated more rapidly and with less cost, thus facilitating further studies of CRP binding
interactions with LDL and other clinically relevant substrates. Human CRP has been expressed
in large quantities in E. coli and found to be functionally indistinguishable from native CRP
(Tanaka et al. 2002); however, purified recombinant CRP from E. coli can retain endotoxin
contaminants unsuitable for in vivo animal studies. The human protein was recently also
expressed in P. pastoris for mass spectrometry studies; however, it was found to contain the
additional N-terminal amino acid sequence EAEA, a result of incomplete processing to remove
α-mating factor at the kexin cleavage site (Kilpatrick et al. 2012). While these additional amino
acids did not adversely impact their efforts to improve standardization of CRP assays, the use of
recombinant CRP for animal studies of atherosclerosis requires proteins without such inadvertent
differences.
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Chapter 4 shows the use of P. pastoris for secreted expression of human wild type CRP
as a correctly folded, functional pentamer with yields in excess of 3.5 mg/L in growth media.
The substitution variant CRP E42Q was also expressed, at over 1.5 mg/L. Recombinant CRP
and CRP E42Q were identified and quantified by ELISA using anti-CRP antibodies. Wild type
CRP and E42Q were PCh affinity purified for comparison to native human CRP. Purified wild
type CRP was characterized by SDS-PAGE under reducing conditions and found to exist in 2
distinct monomeric forms of slightly different mass. These could not be separated from each
other despite the use of PCh affinity chromatography, anion exchange, and gel filtration and both
forms were labeled by CRP-specific antibodies on a Western blot. This result is possibly an
anomaly of the specific yeast clone that was selected during the screening process and that other
transformants containing the same insertion cassette may express CRP in only the correct form.
Further investigation is warranted to solve these problems and generate recombinant CRP
suitable for in vivo animal studies.

Specific Aims
Aim 1: Express functional recombinant human enteropeptidase light chain (hEP L) with amino
acid substitutions to characterize and modify the contributions of residues 96 and 174 to
the extended substrate specificity of the enzyme.
Aim 2: Express the functional recombinant neutrophil serine proteases (NSPs) human neutrophil
elastase (HNE) and human neutrophil cathepsin G (CatG) with intact C-terminal peptide
tails.
Aim 3: Express the functional pentamer of native human C-reactive protein (CRP) and the
substitution variant CRP E42Q.
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Abstract
The serine protease enteropeptidase exhibits a high level of substrate specificity for the
cleavage sequence DDDDK~X, making this enzyme a useful tool for the separation of
recombinant protein fusion domains. In an effort to improve the utility of enteropeptidase for
processing fusion proteins and to better understand its structure and function, two substitution
variants of human enteropeptidase, designated R96Q and Y174R, were created and produced as
active (>92%) enzymes secreted by P. pastoris with yields in excess of 1.7 mg/Liter. The
Y174R variant showed improved specificities for substrates containing the sequences DDDDK
(kcat/KM = 6.83 x 106 M-1 sec-1) and DDDDR (kcat/KM = 1.89 x 107 M-1 sec-1) relative to all other
enteropeptidase variants reported to date. BPTI inhibition of Y174R was significantly decreased.
Kinetic data demonstrate the important contribution of the positively charged residue 96 to
extended substrate specificity in human enteropeptidase. Modeling shows the importance of the
charge-charge interactions in the extended substrate binding pocket.
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Introduction
Enteropeptidase (EC 3.4.21.9), originally named enterokinase, is a trypsin-like serine
protease that activates pancreatic digestive enzymes in the duodenum1-7. The proteolytically
active light chain has high selectivity for the sequence DDDDK (D4K)8,9. Physiologically,
enteropeptidase removes the N-terminal pro-peptide of trypsinogen by cleaving the sequence
D4K~IVGG to activate trypsin. Genetic deficiencies of enteropeptidase have been reported in
two families with symptoms of intestinal malabsorption, diarrhea, and growth failure, revealing
the importance of human enteropeptidase (hEP) in the digestive process10,11. Inhibitors of
enteropeptidase have been designed and tested in a murine model to evaluate their efficacy as
anti-obesity drugs12.
Although some non-specific cleavages have been reported for this enzyme6,13-16, the high
selectivity of enteropeptidase light chain (EPL) for the sequence D4K~X makes it useful as a
biotechnological tool for site-specific separation of recombinant fusion protein domains17,18.
Recombinant bovine enteropeptidase light chain (rbEPL) has been expressed in Pichia
pastoris19,20, Saccharomyces cerevisiae21, and Escherichia coli18,22,23. The monomeric rbEPL
from E. coli proved superior to the native heterodimeric bEP at cleaving fusion proteins18.
Human EPL has greater catalytic efficiency compared to bovine EPL for D4R~X and D4K~X
substrates24,25 and recombinant human enteropeptidase light chain (rhEPL) was shown to have a
10-fold higher specificity constant (kcat/KM) for the D4K~X sequence than bEPL26.
The x-ray crystal structure (PDB code: 1EKB) for bEPL in complex with the inhibitor
VD4K-chloromethane was used in conjunction with rbEPL variants from a baculovirus
expression system to reveal the critical role of K99 (chymotrypsinogen numbering system) in the
S2-S4 (Schechter-Berger system)27 extended binding site that interacts with Asp P2-P4 substrate
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residues27,28. A recent study used the human-to-bovine substitutions R96K and K219Q to shift
the catalytic properties of rhEPL to more closely parallel bEPL, demonstrating additive
contributions of positive residues R96 and K219 to improved extended specificity29. They
constructed in silico models of hEPL based on the bEPL x-ray structure28 and proposed that R96
may shield the P2 residue from the solvent better than K96 and that K219 may form salt bridges
with Asp-P3 and Asp-P529. Others created, in E. coli, a Y174R variant of bEPL that showed an
approximate four-fold improvement in specificity toward the GD4K~IVGG substrate due to
proposed salt bridges by R174 with Asp-P3 and Asp-P422. Recently, a supercharged rhEPL
(rhEPLsc) was created in E. coli to improve enzyme solubility and refolding yields30,31 and an xray crystal structure of this mutant was obtained (PDB code: 4DGJ)28,30,31.
In an effort to improve the utility of rhEPL for processing fusion proteins and to better
understand the structure and function of hEPL, two rhEPL variants were created and produced as
active enzymes secreted by P. pastoris. Kinetic analyses employed synthetic D4K and D4R pnitroanilde (D4K-pNA and D4R-pNA) substrates and the N-α-carbobenzyloxy-L-lysinethiobenzyl ester (Z-Lys-SBzl) substrate for comparison with other reports. Potential Asn-linked
glycosylation sites were mutated to Gln to yield non-glycosylated proteins. In one variant,
arginine was replaced with glutamine at position 96 to create R96Q; furthermore, the kinetic
properties of this variant in comparison with others suggests that the human R96 residue
influences extended substrate affinity through charge-dependent interaction with Asp-P2. In the
second variant (Y174R), tyrosine at residue 174 was replaced with arginine, which has been
shown to improve the specificity in rbEPL22. The human Y174R enzyme shows the highest
specificity for the Asp4 motif of any EPL variant reported to date.
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Results
Protein Engineering and Molecular Cloning
The amino acid sequences for the variants R96Q and Y174R were designed based on the
sequence of native hEPL (Figure 2.1). Due to the tendency of P. pastoris to hyper-glycosylate
secreted proteins32-36, the conservative amino acid substitutions N75Q, N113Q, N135Q, and
N175Q were used to disrupt four potential Asn-linked glycosylation sites in both R96Q and
Y174R (Figure 2.1). The Furin-like protease kexin (Kex2) of the Golgi apparatus in P. pastoris
can cleave dibasic sequences such as KR~X37. The substitution R98Q was incorporated into
both R96Q and Y174R variants to eliminate a potential internal kexin cleavage site (Figure 2.1),
supported by data that an R98A substitution does not reduce the activity of bEPL28. DNA coding
for the human R96Q and Y174R mutants was commercially codon-optimized for expression in
P. pastoris, synthesized, and cloned into the pPICzα A plasmid for secreted expression.
Plasmids encoding R96Q or Y174R were used to transform the X-33 strain of P. pastoris and the
most productive clones were identified in a screening protocol. During secretion, the Kexin
protease removes α-mating factor via cleavage of the sequence KR~IVGG, resulting in secretion
of active R96Q or Y174R variants. Approximately 1.7 mg/L of active R96Q and 2.2 mg/L of
active Y174R, as estimated by Z-Lys-SBzl activity, were expressed in 5 L batches of bioreactor
fermentation. Untransformed X-33 P. pastoris do not secrete enzymatic activity for the Z-LysSBzl substrate.
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Figure 2.1: EPL Sequence Alignment. Human and bovine EPL aligned with human R96Q and
Y174R variants. All engineered substitutions appear in bold and residues 96 and 174 are labeled
with stars. Asn-to-Gln substitutions (bent arrows) disrupt four potential Asn-linked
glycosylation sties. The substitution R98Q (dot) eliminates one possible kexin cleavage site.
Serine protease active site residues (triangles) are also indicated.

Purification
Both enzymes were recovered from culture media by affinity chromatography using the
reversible, Kunitz-type protease inhibitor, Soybean Trypsin Inhibitor (STI). The R96Q and
Y174R variants were purified 1352-fold and 969-fold, respectively, from fermentation media
(Table 2.1). Although the total protein recoveries of purified R96Q and Y174R were similar, the
total and specific activities were unexpectedly low for Y174R (Table 2.1). Assays during
56

purification were in the absence of CaCl2 or Triton X-100, which were subsequently found to
enhance the activity of Y174R consistent with a report on solubility problems with recombinant
hEP30.

Subsequent kinetic analyses including 0.02 mM CaCl2 and 0.01% Triton X-100 show that
both variants have similar KM and kcat values for Z-Lys-SBzl (Table 2.2), suggesting that Y174R
is less soluble than R96Q. The single-step STI affinity purification yielded highly purified
enzymes (Figure 2.2a) and the A280-based concentration estimates were confirmed to within 8%
by active site titration38.

Identity Confirmation and Stability Analyses
The purified recombinant enzymes were analyzed by SDS-PAGE (Figure 2.2a),
confirming high levels of purity at the predicted molecular weight of 26 kDa for nonglycosylated rhEPL. Western blot analysis (Figure 2.2b) further confirms the identities of the
rhEPL variants using a monoclonal antibody against bEPL with non-glycosylated rbEPL as a
positive control. Both substitution variants selectively cut an enteropeptidase cleavage control
protein (CCP; EMD Millipore) with the same cleavage pattern as observed for Tag*off™
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positive control enzyme (Figure 2.2c). Tag*off™ is a non-glycosylated recombinant hEPL
(EMD Millipore).

Figure 2.2: Molecular Characterization of Purified EPL Variants. (A) SDS-PAGE shows
high purity and correct mass (~26 kDa) for non-glycosylated enteropeptidase variants R96Q and
Y174R. (B) Monoclonal antibody against bEPL also labels human variants R96Q and Y174R by
Western blot. (C) Cleavage assay shows that R96Q and Y174R variants cleave the CCP like
Tag*Off™.
Over the course of five days, Tag*off™, R96Q, and Y174R were evaluated for stability
at 37 °C in 100 mM Tris, 0.02 mM CaCl2, 0.01% Triton X-100, pH = 8.0. Tag*off™ and R96Q
had half-lives longer than one week (16 days and 9 days, respectively); however, the Y174R
substitution reduced the half-life to 48 hours (Figure 2.3). Residue R174 may provide a target
for EPL autolysis. All of the enzymes showed long-term stability in low pH storage buffers at
+4 °C and -20 °C.
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Figure 2.3: Enzyme Stability Assay. Tag*Off™ (diamonds) has an estimated half-life of 16
days. R96Q (squares) has an estimated half-life of 9 days. Y174R (circles) has an estimated
half-life of 48 hours. Error bars show standard deviation of triplicate data. Regression analyses
were fit to the equation ½ = e-kt.

Kinetic Analyses
The Michaelis Constant KM, the catalytic rate constant kcat, and the specificity constant
kcat/KM were evaluated for Tag*off™, R96Q, and Y174R using the synthetic peptide substrates
Z-Lys-SBzl, GD4K-pNA, and GD4R-pNA (Table 2.2). These assays were conducted in 100mM
Tris, 0.02 mM CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0. CaCl2 enhances EPL activity
at the 0.02 mM concentration26. NaCl was excluded because it has been shown to reduce EPL
activity for GD4K-na26. Due to the limited supply of Tag*off™, the stock concentration of
active Tag*off™ could not be determined by active site titration; consequently, all Tag*off™
kcat values reported here are estimates based on the averages of the values for the R96Q and
Y174R variants, which are very similar (Table 2.2); furthermore, the estimate reported here for
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Tag*off™ with GD4K-pNA is similar to the kcat reported elsewhere for hEPL with the substrate
GD4K-na26.

For the single residue substrate Z-Lys-SBzl, no statistically significant differences were
observed among the KM values; likewise, the kcat value for R96Q is only 1.1 times that for
Y174R (P<0.05) (Table 2.2). The comparison of kcat/KM ratios reveals that R96Q cleaves Z-LysSBzl about 1.2 times as efficiently as either Tag*off™ (P<0.05, estimated) or Y174R (P<0.05)
(Table 2.2). The Y174R variant and Tag*off™ do not have statistically different kcat/KM values.
For the substrate GD4K-pNA, the enzymes behave very differently. The Y174R variant
shows the smallest KM for this substrate (Table 2.2). The KM for Tag*off™ is 1.6 times larger
than for Y174R (P<0.01) (Table 2.2). With the weakest affinity for GD4K-pNA, R96Q has a KM
that is 9.3-fold greater than Tag*off™ (P<0.0005) and 15.5-fold greater than the Y174R variant
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(P<0.0005) (Table 2.2). The kcat of R96Q was 1.2-fold that of Y174R (P<0.005) (Table 2.2).
The single amino acid substitution Y174R improved the catalytic efficiency for the GD4K-pNA
substrate by 1.5-fold compared to Tag*off™ (P<0.01, estimated) (Table 2.2, Figure 2.4). The
specificity of R96Q for D4K-pNA showed only 12% of the value for Tag*off™ (P<0.0001,
estimated) and only 8% of the Y174R result (P<0.0001) (Table 2.2, Figure 2.4). Compared to
100 mM Tris HCl, pH = 8.0, the addition of 0.02 mM CaCl2 and 0.01% Triton X-100 improved
the specificity constants of R96Q and Y174R by 6 times and 20 times, respectively, for GD4KpNA.

Figure 2.4: Specificity Constants. Specificity constants of Tag*Off™, R96Q, and Y174R for
the extended substrates GD4K-pNA and GD4R-pNA are shown. All values are mean average ±
standard deviation, as listed in Table 2.2. P < 0.005 for all * and ** comparisons.
KM values for GD4R-pNA were lowest for Y174R, followed by Tag*off™ at 2.4 times
Y174R (P<0.005) and then R96Q at 6.9 times Y174R (P<0.001) (Table 2.2). As with the other
two synthetic substrates, the kcat values of R96Q and Y174R are very similar. The kcat/KM
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specificity constant of Y174R for the GD4R-pNA substrate is 2.6 times that of Tag*off™
(P<0.005, estimated) and 8-fold that of R96Q (P<0.005) (Table 2.2, Figure 2.4). The kcat/KM for
Tag*off™ is 3 times that of R96Q (P<0.005, estimated) (Table 2.2, Figure 2.4). Compared to
100 mM Tris HCl, pH = 8.0, the addition of 0.02 mM CaCl2 and 0.01% Triton X-100 improved
the specificity constants of R96Q and Y174R for GD4R-pNA by 6.8 times and 28 times,
respectively.
Comparison of the relative efficiencies of each enzyme for the extended peptide synthetic
substrates reveals that the GD4R-pNA sequence is preferred over GD4K-pNA by all variants,
especially for Y174R, by 2.8 times (P<0.01) (Table 2.2, Figure 2.4). The Tag*off™ enzyme
only showed 1.3 times greater selectivity for GD4R-pNA (P<0.005) compared with GD4K-pNA,
although the KM was reduced by 42% (Table 2.2, Figure 2.4). While R96Q had the lowest
specificity constants with either of the extended peptide substrates, its preference for GD4R-pNA
was 4.3 times that of GD4K-pNA (P<0.005) (Table 2.2, Figure 2.4).
The substitution Y174R significantly decreases the binding affinity for the inhibitor BPTI
(Table 2.3). The inhibition equilibrium constant, Ki, is 4 times larger for Y174R (P<0.0001)
than for Tag*off™ and 3.6 times larger (P<0.0001) than for R96Q (Table 2.3). The R96Q
substitution did not significantly change the Ki from that of Tag*off™ (Table 2.3).
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Discussion
The extended substrate binding pocket of EPL can be thought of as a five-walled cage
where residues 96, 99, 174, and 219 form walls 1-4 (Figure 2.5), with the active site (S195) and
the S1 specificity pocket (D189) forming the floor. The open fifth wall and the open ceiling of
the cage allow the substrate to enter. In all variants, “wall 2” (K99) and the “floor” are required
for D4K specificity28. Added specificity comes from the properties of the other walls. In bEPL,
“wall 1” is K96, “wall 3” is Y174, and “wall 4” is Q219 (Figure 2.5a). The positive charge of
K96 has been shown to improve specificity28; however, Y174 contributes only a weak hydrogen
bond between the tyrosine hydroxyl group and the carboxyl side chain of Asp-P328. In the study
of the E. coli variant rbEPL Y174R (Figure 2.5b), the presence of the ε-guanidino group of R174
on “wall 3” of the cage was shown to improve extended substrate specificity and was proposed
to form a salt bridge with Asp-P322. According to the x-ray crystal structure of bEPL (Figure
2.5a), Q219 side chain does not interact with the substrate in any way, extending away from the
binding site instead.
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Figure 2.5: Electrostatic Models of EPL Extended Binding Pockets. Proposed electrostatic
models show EPL binding pockets with bound D3K substrate. Positively charged (blue) residues
(green labels) improve binding affinity for Asp P2-P4. Negative charges are red. (A) Bovine
EPL (PDB Code: 1EKB). (B) Bovine EPL with Y174R substitution. (C) Human EPL (by
substitution of PDB model 4DGJ). (D) Human EPL with Y174R substitution. (E) Supercharged
human EPL (PDB code: 4DGJ). (F) Human EPL with R96Q substitution.
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The improved specificity of hEPL over bEPL can be attributed in part to differences in
two of the cage walls (Figure 2.5a and 2.5c) and in part to species-specific differences in the
stability of the active site and specificity pocket29. First, amino acid substitution by others has
shown that R96 stabilizes Asp-P2 better than K9629. Second, another substitution by the same
group has also shown that K219 improves the substrate specificity of rhEPL compared to Q219,
especially in conjunction with R9629. The positively charged K219 side chain amino group may
by attracted toward the binding site in the presence of Asp-P3 in hEPL29 to form “wall 4” (Figure
2.5c, 2.5d, and 2.5f) whereas Q219 and D219 side chains extend into the solvent in the crystal
structures of bEPL28 (Figure 2.5a and 2.5b) and rhEPLsc34 (Figure 2.5e).
The human Y174R variant presented here combines the improved specificity of the
bovine Y174R substitution22 with the positive influences of residues R96 and K21929 in the
human enzyme. The result is the novel human Y174R (Figure 2.5d) with improved extended
substrate specificity relative to previously reported rEPL variants. This Y174R enzyme may
prove advantageous for the separation of recombinant protein fusion constructs. Although
Y174R has only a slightly better specificity than Tag*off™ for the D4K sequence, Y174R
displays a very high specificity constant for the D4R sequence (Table 2.2, Figure 2.4). This
reduces nonspecific cleavage by Y174R in the presence of excess fusion protein if the D4R linker
is employed. The shorter enzyme half-life of Y174R may be due to autolysis at R174. Although
poor stability is typically undesirable in enzymes, the limited half-life of Y174R under catalytic
conditions (pH = 8.0, 37 °C) may actually contribute to a reduction of non-specific substrate
cleavage relative to native EPL.
The R96Q variant generated during this project reveals that the absence of positive
charge at position 96 reduces the catalytic efficiency by 94% relative to Tag*off™ for D4K and
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by 68% relative to Tag*off™ for D4R (Table 2.2, Figure 2.4). Others have shown that the K96A
substitution in rbEPL reduces its specificity by approximately 80% of native bEPL for GD4Kna28. It has also been previously shown that the human-to-bovine substitution rhEPL R96K
reduces its specificity by only about 6% relative to rhEPL29. These data suggest that the positive
charge of residue 96 contributes significantly to the substrate specificities of all EPL variants,
despite crystallographic evidence suggesting that K96 in bEPL does not coordinate with AspP228.
Examination of an x-ray crystal structure of the β-trypsin + BPTI complex (PDB code:
3OTJ)39 aligned with the structure of EPL reveals that BPTI residue Arg39 lies in close proximity
to EPL residue 174. As a result, an electrostatic repulsion likely occurs, accounting for the
approximately 5-fold increase in the Ki of Y174R for BPTI.
Non-glycosylated recombinant human enteropeptidase variants Y174R and R96Q were
easily expressed into the growth media of P. pastoris as properly folded active enzymes. Both
enzymes were highly purified by chromatography on immobilized STI. The Y174R variant
displayed increased specificity for the GD4R-pNA substrate relative to a commercial sample of
recombinant human enteropeptidase (Tag*off™). The potential utility of a D4R linker between
fusion proteins24,25 is thus amplified by the use of Y174R. The kinetic properties of R96Q
demonstrate the importance of R96 to the binding of extended peptide substrates.

Materials and Methods
The hEPL amino acid sequence was taken from NCBI Ref. Seq. NP_002763.2. DNAs
were codon-optimized and synthesized by different companies; R96Q by GenScript and Y174R
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by DNA 2.0. The recombinant human EPL named Tag*off™ and a cleavage control protein
(CCP) were products of EMD Millipore.

Molecular Cloning
The DNA sequences for R96Q and Y174R were cloned into the pPICzα A plasmid (Life
Technologies). The linearized vectors were used to transform X-33 strain P. pastoris (Life
Technologies) by electroporation. Transformants were selected on YPDS agar plates with 100
µg/mL Zeocin and 100 µg/mL Ampicillin. Selected colonies were grown in 12-well microtiter
plates as 2 mL cultures in synthetic minimal medium (SMM) (10 g/L MSG, 2.5 g/L (NH4)2SO4,
100 mM KH2PO4 at pH = 5.0, 13.4 g/L YNB, and 0.4 mg/L biotin) containing 0.5% methanol40.
Cultures were grown for four days at room temperature with daily addition of 0.5% methanol.
Culture supernatants were tested for enteropeptidase activity using the synthetic substrate Z-LysSBzl and activities were normalized to wet cell pellet weights (WCW) for selection of the best
expressers.

Fermentation
Cultures were grown using the strategy in the Life Technologies Pichia Fermentation
Process Guidelines, with some modification. Basal salts medium (BSM) contained 26.7 mL/L
H3PO4, 18.2 g/L K2SO4, 14.9 g/L MgSO4, 4.13 g/L KOH, 40 g/L glycerol and was modified by
adding 10 g/L MSG and 2.5 g/L (NH4)2SO440. CaSO4 was omitted to reduce the formation of
insoluble calcium phosphates. BSM was supplemented with PTM4 trace elements41. Antifoam
204 (0.5 mL/L) was used to prevent foaming. Fermentation occurred at pH at 5.0 and pure O2

67

was used to maintain the dissolved O2 content (dO2) at 35% by regulating the impeller speed.
Culture density and protein accumulation were monitored daily.

Purification
Culture supernatants, adjusted to pH = 8.0, were centrifuged and filtered through glass
fiber pre-filters and 0.45 µm PE filters. Enzymes were affinity purified at pH = 8.0 on an
agarose column with immobilized Soybean Trypsin Inhibitor (STI). The wash buffer contained
50mM Tris, 0.5 M NaCl, pH = 8.0 while 50 mM acetic acid, 0.5 M NaCl, pH = 3.5 was used for
protein elution. Active fractions (Z-Lys-SBzl) were pooled and concentrated by ultrafiltration on
a 10K MWCO membrane (Millipore) and stored in 100 mM glycine, pH = 3.0. Active site
titrations of R96Q and Y174R were performed with 4-methylumbelliferyl-p-guanidinobenzoate
(MUGB)38.

SDS-PAGE and Western Blotting
SDS-PAGE was performed with 12% (Figure 2.3a and 2.3b) or 4-12% (Figure 2.3c)
NuPAGE gels using MOPS SDS running buffer (Life Technologies) and stained with NuBlu
Coomassie stain (NuSep). Western blot on PVDF was blocked for 1 hour in TBST + 1% BSA
at 20 °C, then reacted with 0.1 µg/mL of a mouse monoclonal antibody against bEPL (GenScript)
in TBST. After washing with TBST, the blot was then incubated for 1 hour with HRPconjugated goat anti-mouse antibody (0.08 µg/mL) in TBST (Pierce), washed in TBST, and
visualized using Super Signal West Pico ECL (Pierce). Images were captured and processed
using a GBox (Syngene).
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Cleavage of CCP
CCP was incubated with Tag*off™, R96Q, or Y174R enzyme at 37 °C in 20 mM TrisHCl, 50 mM NaCl, 2 mM CaCl2, pH = 7.4 (provided with Tag*off™). At 2 hours and 6 hours,
samples were collected and frozen (-20 °C) prior to SDS-PAGE analysis.

Stability Assay
Enzymes were incubated for five days at 37 °C in 20 mM Tris-HCl, 50 mM NaCl, 2 mM
CaCl2, pH = 8.0 and daily samples were stored at -20 °C prior to assays in 300 µM Z-Lys-SBzl,
100 mM Tris, 0.02 mM CaCl2, 0.01% Triton X-100, 10% DMSO, 1 mM DTNB, pH = 8.0.

Kinetic Assays
All enzyme activity assays were conducted in 100 µl format on a 96-well microtiter plate
reader at 25 °C ± 0.5 °C. All substrate stocks were freshly dissolved in DMSO. The assay
conditions were 100 mM Tris, 0.02% CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0.
Assays with 0.05-1.0 mM Z-Lys-SBzl (Sigma or Bachem) also included 1 mM DTNB42,43. The
extended peptide substrates GD4K-pNA and GD4R-pNA (LifeTein) were used at concentrations
between 0.02-1.0 mM and 5-100 μM, respectively. Reactions were initiated by adding enzyme
to a 2nM final concentration into premixed buffer and substrate. Absorbances at 410 nm were
followed kinetically for 10 minutes. Product extinction coefficients were 13,600 M-1 cm-1 for the
thiobenzyl assays and 8,800 M-1 cm-1 for p-nitroaniline. The kinetic parameters KM and kcat were
determined by hyperbolic regression analysis of data using Hyper32 (J. Easterby, ©2003).
BPTI inhibition assays were conducted in the same format and with 100 mM Tris, 0.02%
CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0, containing 1mM DTNB and using 300-600
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μM Z-Lys-SBzl as the substrate. Here, 2 nM enzyme concentrations were premixed with 50-600
nM BPTI and incubated at room temperature for 15 minutes prior to the addition of Z-Lys-SBzl
to initiate the reactions. Dixon plots were generated from the reaction velocity data to determine
the Ki values44.

Molecular Modeling
Modeling was performed in Discovery Studio 3.1 (Accelrys), using bEP L (PDB code:
1EKB) (Figure 2.5a) to create the proposed model of rbEPL Y174R (Figure 2.5b) by single
amino acid substitution. This side chain was repositioned by manual bond rotation, compared to
the previously proposed position of R17422, and its geometry was cleaned using the software’s
Dreiding-like force field. The structure of rhEPLsc (PDB code: 4DGJ) provided the template for
modeling all human EPL variants in complex with the D3K substrate (taken from 1EKB). The
key residues R96, R174, and K219 were repositioned, as above, in comparison with previous
reports22,29 to reflect possible interactions with the D3K substrate (Figure 2.5c, 2.5d, 2.5e, and
2.5f). Residue Q96 (Figure 2.5f) positioning could not be predicted based on currently available
data.
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Abstract
Recombinant human neutrophil elastase (rHNE) and human Cathepsin G (rhCatG) were
expressed with intact C-terminal pro-peptide extensions in the yeast Pichia pastoris and, with
limited success, in the yeast Kluyveromyces lactis. Both enzymes were engineered as fusion
proteins linked to the heme-binding domain of cytochrome B5 (CytB5) and hexahistidine
(6xHis) tag by an enteropeptidase-cleavable linker sequence, forming protease zymogens. Both
full-length fusion proteins were secreted into the growth media of P. pastoris and partially
purified by immobilized metal affinity chromatography for the 6xHis tag, furthermore, the
partially purified enzymes displayed absorbance at 410 nm that characterizes heme-bound
recombinant CytB5 fusion proteins. Both rHNE and rhCatG were activated from their zymogens
upon treatment with enteropeptidase, and the concentrations of both activities corresponded to
the intensities of absorbance at 410 nm. This is the first report of successful recombinant
expression of proteolytically active HNE and hCatG in any microorganism, as well as the first
report of the use of CytB5 as a recombinant fusion protein domain in any eukaryotic
recombinant expression system. Neither active enzyme was successfully purified to
homogeneity, despite repeated attempts using multiple ion exchange chromatography and
affinity chromatography for the specific, reversible serine protease inhibitors basic pancreatic
trypsin inhibitor (BPTI, Trasylol®) and secretory leukocyte proteinase inhibitor (SLPI).
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Introduction
The neutrophil serine proteases (NSPs) human neutrophil elastase (HNE; EC 3.4.21.37)
and cathepsin G (CatG; EC 3.4.21.20) act in multiple ways during acute inflammatory and
immune responses1-3. Both HNE and CatG, along with a third NSP, Proteinase 3 (Pr3,
Myeloblastin), reside in primary (azurophil) granules of neutrophils (polymorphonuclear
leukocytes, PMNs)4,5 and act against pathogenic bacteria6-10 and fungi11-13, by intracellular6,7,11,14
and extracellular13,15-18 means. In addition to proteolytic and non-proteolytic19-25 antimicrobial
properties, HNE and CatG also process various cytokines26-28, chemokines29-34, and protease
activated receptors (PARs)35,36 to participate in inflammatory regulation and cell signaling1-3. In
the BRENDA enzyme database, more information and links to research articles can be found for
HNE (http://www.brenda-enzymes.org/php/result_flat.php4?ecno=3.4.21.37) and for CatG
(http://www.brenda-enzymes.org/php/result_flat.php4?ecno=3.4.21.20).
Many mutations of the HNE-coding gene (ELANE) result in cyclic37-40 or severe
congenital39,41-45 forms of hereditary neutropenia, diseases of neutrophil maturation characterized
by reduced numbers of neutrophils in circulation and increased susceptibility to infections, and
these mutations affect HNE activity in different ways46. Chain-terminating mutations in ELANE
have been identified, localized to the final (fifth) exon, that lead to translation of HNE lacking a
complete C-terminus47 and these mutations are closely associated with severe congenital
neutropenia (SCN)46; however, the roles of the C-terminus of HNE are unclear.
All chymotrypsin-like serine proteases, including NSPs3,48-50, are initially translated as
inactive precursors containing N-terminal signal sequences and activation dipeptides; however,
the NSP precursors also possess unusual C-terminal propeptide tails of varying length that do not
resemble each other and whose functions are not known47,51,52. These tails are removed post
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translationally by an unidentified protease and they are not required for trafficking of NSPs to
neutrophil primary granules1,47,53. HNE with an intact C-terminal tail, but not Pr3, is directed, at
least in part, through a detour to the cell membrane, from where it is re-internalized by
endocytosis53; however, it is unclear if this is also true for CatG. HNE contains a binding site for
the µ3a subunit of AP3 that is only exposed after removal of the C-terminal tail54 but it appears
that this is not how AP3 and HNE interact during trafficking53. Instead, the tetraspanin CD63
has been shown to associate with HNE to mediate AP3-dependent granule delivery55, although
the CD63 binding site on HNE has not been identified. The roles of the C-terminal tail of CatG
have not been investigated as thoroughly as HNE and the function of the tail is still unknown.
Although others have previously expressed variants of HNE and CatG in mammalian
cells51,56-58, active variants of these enzymes have not been expressed in sufficient quantities for
most biochemical studies. Recombinant variants of active HNE and active CatG containing
intact C-terminal tails have also not been expressed and may facilitate investigations into the
function(s) of NSP C-termini and the mechanism(s) responsible for their removal. CatG also
exhibits a broad, duel specificity for both trypsin- and chymotrypsin- like substrates59,60 that is
attributed to the negative charge of Glu 226 (chymotrypsinogen numbering system) at the base of
a deep, relatively hydrophobic S1 binding pocket (Schechter-Berger numbering system)61.
Recombinant expression of CatG in milligram or gram quantities would enable studies of amino
acid substitutions to affect changes in CatG substrate specificity.
HNE and CatG were expressed successfully as secreted, recombinant fusion proteins in
the yeast P. pastoris and secreted expression attempts were also made, with limited success, in a
similar expression system based on the yeast K. lactis. Both enzymes were produced with intact
C-terminal pro-domain tails as protease zymogens whose enzymatic functions were activated by
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the enteropeptidase (EP) -mediated removal of an N-terminal heme-binding cytochrome B5
(CytB5) domain. The fusion proteins also had the heme-binding properties of CytB5; exhibiting
absorbance maxima at 410 nm that facilitated the partial purification by immobilized metal
(Ni2+) affinity chromatography (IMAC) affinity for an N-terminal hexahistidine (6xHis) tag.
Attempts to further purify the activated recombinant enzymes to homogeneity were unsuccessful
and require further investigation.

Results and Discussion
Protein Modifications and Fusion Protein Design
NSP Domains and Modifications. The recombinant HNE (rHNE) and recombinant
human CatG (rhCatG) amino acid sequences (Figure 3.1), starting at residue Ile16
(chymotrypsinogen numbering) and including intact C-terminal extensions, were designed from
the known sequences of native HNE (NCBI Ref. Seq. NP_001963.1) (Figure 3.1a) and hCatG
(NCBI Ref. Seq. NP_001902.1) (Figure 3.1b). An N-terminal EP-cleavable linker sequence,
DYKDDDDK, was added to each (Figure 3.1). Conservative substitutions were made to disrupt
potential glycosylation sites because P. pastoris often hyper-glycosylates secreted proteins62-66.
In rHNE, three potential N-linked glycosylation sites were disrupted by the substitutions N72Q,
N109Q, and N159Q; similarly, one predicted N-linked glycosylation site was disrupted in
rhCatG by the substitution N65Q. One potential O-linked glycosylation site was disrupted in
rHNE by the substitution S260N; however, this created a potential N-linked glycosylation site.
Alternatives to this substitution were considered, and this issue was resolved by the additional
substitution T262A.
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Figure 3.1: Amino acid sequence alignments. Alignments of (A) native HNE and engineered
rHNE, with N-terminal EP cleavage site extension DYKDDDDK, or (B) native hCatG and
engineered rhCatG, also with DYKDDDDK, highlight key features and differences. The Nterminal Ile 16 residue ( ) and the catalytic triad residues ( ) that are necessary for proteolytic
activity, as well as the Glu 226 residue ( ) that confers trypsin-like substrate specificity, appear
in green. Substitution sites to disrupt potential N-linked ( ) and O-linked ( ) glycosylation
appear in orange and purple, respectively. Arg-to-Gln substitutions ( ) to reduce the pI and
eliminate potential kexin cleavage sites appear in blue. The C-terminal pro-peptide tails that are
removed during neutrophil maturation appear in bold with red underline.
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Both P. pastoris and K. lactis express similar furin-like kexin proteases that can cleave
dibasic sequences such as KR~X and RR~X67,68. In rHNE, the substitutions R21Q, R76Q,
R128Q, and R178Q were used to disrupt four potential kexin cleavage sites (Figure 3.1a) and, in
rhCatG, the substitutions R76Q, R86Q, R111Q, R114Q, R148Q, R178Q, R186Q, and R188(a)Q
were similarly used (Figure 3.1a). The replacement of highly basic Arg residues with Gln at
these sites also reduced the calculated isoelectric points of both rHNE, from 9.7 to 8.7, and of
rhCatG, from 11.9 to 10.9. This is thought to be beneficial because it has been shown that a
comparatively high protein isoelectric point correlates with poor expression in P. pastoris69.
Cytochrome B5 Recognition and Purification Domain. Separately, the amino acid
sequence of a fusion domain was designed for addition to the N-terminus of the rHNE and
rhCatG proteins. This fusion domain consists of the soluble heme-binding domain of
cytochrome B5 (CytB5) from Rattus norvegicus (NCBI Ref. Seq. NP_071581.1) with an Nterminal hexahistidine (6xHis) tag for IMAC purification and antibody-based detection70-72. The
CytB5 domain has been used previously to produce, in E. coli, heme-binding recombinant
proteins with a distinctive spectrophotometric absorbance peak at the wavelength λ = 410
nm71,72. Additionally, the CytB5 fusion decreased the pI of the secreted protein and prevented
premature activation of the enzymes which could have been damaging to the yeast cells.
Fusion Protein Zymogens. Based on the three modified amino acid sequences, three
protein-coding genes were codon-optimized for recombinant expression in P. pastoris and K.
lactis and synthesized as cDNAs with suitable restriction sites for subsequent plasmid
construction. Expression plasmids were assembled in two stages and used to successfully
transform P. pastoris and K. lactis.
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Figure 3.2: Fusion Construct Schematics. The multi-domain structure of the rhCatG and
rHNE fusion constructs, starting with the N-termini on the left. The α-mating factor yeast
secretion signal pre-domain (yellow) directs both polypeptide chains to the secretory pathway.
In the Golgi, the protease kexin (Kex2) cleaves the Kex2 site (blue) KR~H to remove the predomain. This exposes the N-terminal 6xHis tag (orange) of the purification and activation prodomain of the secreted, inactive, mature zymogen. The cytochrome B5 domain (red) of the
mature zymogen exists in a heme-bound state. The treatment of these constructs with the serine
protease enteropeptidase (EP) specifically cleaves the D4K~I peptide bond of the EP site to
activate rhCatG and rHNE (green) by removing the pro-domain to expose the N-terminal Ile16
of either enzyme.

The fusion proteins encoded by these plasmids contain multiple domains intended to
facilitate the expression, secretion, purification, identification, and activation of the enzymes
rHNE and rhCatG. The initial intracellular products of gene translation include, at their Ntermini, the yeast α-mating factor signal sequence that directs the protein for secretion and is,
subsequently, removed by kexin in the Golgi apparatus (Figure 3.2). The final secreted protein
contains an N-terminal 6xHis tag and CytB5 heme-binding domain connected by the EPcleavable linker sequence to the rHNE or rhCatG protease domain (Figure 3.2). The constructs
are protease zymogens that can only be activated through cleavage of the sequence DDDDK~I
by enteropeptidase to separate the protease domains from their fusion partners and expose the
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native Ile16 N-termini that are necessary for the activity of all S1 clan serine proteases (Figure
3.2)73.

Transformation and Screening
P. pastoris and K. lactis cells were transformed with linearized insertion cassettes
designed to integrate into the yeast genomes by site-specific homologous recombination into the
AOX1 transcriptional promoter of P. pastoris or the LAC4 transcriptional promoter of K. lactis.
Positive transformed colonies from agar plates were grown in 2 mL or 10 mL cultures,
depending on the number of transformants, under inducing conditions for four days. After
harvesting, culture supernatants were adjusted to pH = 8.0 and treated overnight with EP and
then tested for rHNE or rhCatG enzymatic activity (units/mL). The wet cell pellet mass (g/mL)
was also determined for each culture, after which the ratio of enzymatic activity to wet cell pellet
mass (units/g) was calculated. Figure 3.3a shows the results for CytB5-rhCatG screening of 44
P. pastoris transformants as an example. The four colonies with the highest ratios were selected
for growth in baffled flasks with equal starting culture densities, to confirm the results obtained
in smaller volumes. In the sample case of rhCatG, the four best colonies were #3, #27, #36, and
#43. Of these, #43 expressed more enzyme than #36 (not shown), which had given the best
results in the smaller volume (Figure 3.3a).
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Figure 3.3: Screening Colonies for rhCatG. (A) Activity (units) per gram of wet cell mass
was calculated for 44 P. pastoris clones grown for 4 days in 2 mL cultures. Clarified culture
supernatants were activated with EP and tested for rhCatG activity (units/mL) using the
chromogenic synthetic peptide substrate Suc-AAPF-SBzl. The weight (g/mL) was determined
for each cell pellet. The four best clones (orange and red bars) were grown in 100 mL cultures in
induction medium, starting at an OD600 = 1, and screened for activity (not shown), finding that
colony #43 (red bar) expressed more activity per cell density than the others. (B) PCR on gDNA
extracted from yeast cell pellets confirms the presence of multiple repeat tandem copies of the
insertion cassette in colony #43 by the appearance of the ~1 kb PCR amplification product.
Colonies #3 and #27 also tested positive, although the bands appear very faint. The negative
control and #36 tested negative. Band intensity does not correlate to the number of genomic
inserts, due to variation in the concentration and integrity of the gDNA samples used as PCR
templates.

Because multiple recombination events can occur within a single cell of either species
during transformation to create a multi-copy integrant, the most productive clones were screened
by PCR to identify those containing multiple genomic copies of the insertion cassette. Genomic
DNA (gDNA) samples were extracted from cell pellets using glass bead disruption,
phenol/chloroform extraction, and ethanol precipitation; furthermore, the integrity of each gDNA
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sample was evaluated by gel electrophoresis. Both PCR tests used primers that only amplified
their product if two adjacent copies of the insertion cassette occurred in tandem in the gDNA.
Results for the CytB5-rhCatG clones #3, #27, #36, and #43 are provided as an example (Figure
3.3b). In this instance, the clone #43 showed a clean PCR product of the correct size (~1 kb) that
confirms clone #43 as a multi-copy integrant. For each yeast species and each fusion protein, a
single clone was identified by this process as the best for continued use.

Protein Expression
The most successful and heavily pursued of the CytB5-rHNE and CytB5-rhCatG fusion
protein expression attempts occurred by fermentation of P. pastoris transformants. Expression
attempts in K. lactis produced only limited success, thus they were abandoned in favor of the P.
pastoris platform. CytB5-rHNE K. lactis fermentation produced less than 100 µg/L of EPactivable rHNE activity against MeO-Suc-AAPV-pNA (less than 150 µg/L CytB5-rHNE);
furthermore, neither the cells nor the culture supernatant displayed 410 nm absorbance peaks and
no red color was visible prior to purification (below). Bioreactor scale fermentation of CytB5rhCatG K. lactis was not pursued due to poor results on a small scale and the limited success of
CytB5-rHNE.
Clarified culture supernatants of both CytB5-rHNE and CytB5-rhCatG strains contained
their respective activities, which were only detectable after activation with EP, but the media did
not exhibit 410 nm absorbance peaks. The CytB5-rHNE supernatants from successful
fermentations of P. pastoris are estimated to have produced between 1.5 and 3.5 mg/L of EPactivated rHNE (between 2.3 and 5.3 mg/L of CytB5-rHNE recombinant protein), as determined
by catalytic activity for the chromogenic synthetic peptide substrate MeO-Suc-AAPV-pNA in
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comparison to known concentrations of purified native HNE. The CytB5-rhCatG P. pastoris
never produced more than 200 µg/L of EP-activated enzyme (~300 µg/L of CytB5-rhCatG
recombinant protein) in fermentation media, compared to purified native hCatG for the substrate
Suc-AAPF-SBzl.
During the methanol induction phase of growth, P. pastoris cultures expressing both
CytB5 constructs developed a dark pink color distinct from the light tan normally seen in P.
pastoris cultures. The majority of this color was retained by cell pellets and only recoverable
upon cell lysis. Clarified cell lysates exhibited the dark red color and 410 nm absorbance peak
indicative of CytB5 protein expression; however, these lysates did not display HNE or CatG
activity before or after treatment with EP.

Partial Purification and Activation: rHNE and rhCatG in P. pastoris
Both CytB5-rHNE and CytB5-rhCatG fusion proteins were partially purified from P.
pastoris fermentation media using immobilized metal (Ni2+) affinity chromatography (IMAC)
for the 6xHis tag; however, efficient recoveries were dependent on buffer exchange by
ultrafiltration of fermentation media prior to purification. Due to the heme-binding properties of
the CytB5 domain, IMAC elution fractions containing purified fusion constructs could be
identified by the presence of 410 nm peaks in their absorbance spectra (Figure 3.4). Purified
fractions of CytB5-rHNE had a distinct absorbance peak at 410 nm in addition to the expected
280 nm absorbance peak (Figure 3.4a); furthermore, fractions with strong 410 nm absorbance
peaks often appeared dark red-brown in color. Purified fractions of CytB5-rhCatG contained an
additional, stronger absorbance peak at 350 nm (Figure 3.4b) and these fractions displayed a dark
green color believed to be attributable to a co-purified contaminant that was not successfully
removed.
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Figure 3.4: Absorbance Spectra for CytB5 Fusion Protease Zymogens After Partial
Purification by IMAC. Partially purified (A) CytB5-rHNE exhibits the characteristic spectrum
for purified CytB5 fusion proteins, with clear absorbance maxima at 280 nm ( ) and 410 nm ( )
accompanied by a visible dark red color. (B) CytB5-rhCatG recovered by IMAC was
contaminated with an unidentified substance that made the eluate visibly dark green instead of
dark red, as confirmed by the additional absorbance maximum at 350 nm ( ) and the increased
A280/A410 ratio relative to (A) CytB5-rHNE.

IMAC elution fractions that contained detectable 410 nm absorbance peaks were
activated by overnight treatment with EP. Levels of subsequent rHNE and rhCatG activities
increased to their maxima as functions of treatment time (data not shown) and correlated by
fraction to the intensity of absorbance at 410 nm, but not 280 nm, suggesting the identity and
partial purification of both enzymes, as in the examples shown (Figure 3.5), where
approximately 600 µg of CytB5-rHNE (Figure 3.5a) and 270 µg of CytB5-rhCatG (Figure 3.5b)
were recovered, as estimated by activity. About 1.2 mg of CytB5-rHNE was recovered from 1 L
of fermentation medium containing approximately 1.5 mg, an 80% recovery yield, during the
most successful purification attempt. Due to limited CytB5-rhCatG expression, 3.5 L of
fermentation medium, concentrated more than 50-fold and containing about 370 µg activable
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enzyme, was necessary to acquire the estimated 270 µg indicated above, a 73% recovery yield.
The ratios of A410/A280 reflect the relative amount of purification by fraction.

Figure 3.5: IMAC elution profiles. Profiles are shown for the partial purification of
(A) CytB5-rHNE and (B) CytB5-rhCatG. Absorbance at 280 nm ( ) shows total protein content
and 410 nm ( ) shows the presence of heme-bound CytB5 fusion domain. Bar graphs show the
enzymatic activity in 25 µL of EP-activated fractions of (A) rHNE for MeO-Suc-AAPV-pNA or
(B) rhCatG for Suc-AAPF-SBzl. Enzymatic activity is proportional to absorbance at 410 nm,
but not 280 nm. The higher ratio of A410/A280 for CytB5-rHNE indicates greater purity
relative to CytB5-rhCatG.
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Figure 3.6: SDS-PAGE and Western Blot for Partially Purified CytB5-rHNE. CytB5rHNE partially purified by IMAC and activated by EP in comparison to native HNE. (A) SDSPAGE under reducing conditions shows partial purification of CytB5-rHNE and activation by
EP. Native HNE is a mixture of three isoforms appearing between approximately 25 – 30 kDa
that vary by glycosylation pattern. Prominent bands appearing between 10 – 15 kDa in the
native HNE sample correspond to fragments of autolysis and also appear in commercial
preparations of purified native HNE. (B) Activated rHNE, but not CytB5-rHNE, detection by
Western blot confirms the identity of active rHNE. The primary antibody was polyclonal rabbit
anti-HNE IgG and the HRP-conjugated secondary antibody was polyclonal goat anti-rabbit IgG.
The 10 kDa band in CytB5-rHNE is unidentified, but may be due to non-specific binding. Two
bands are labeled in the native HNE sample, showing the mature enzyme (~25 kDa) and a
fragment of limited autolysis (< 15 kDa) as in (A).

IMAC purified CytB5-rHNE from P. pastoris, with and without EP pre-treatment, were
analyzed by SDS-PAGE and Western Blot to verify the purity, identity, and activation of the
recombinant construct (Figure 3.6). SDS-PAGE under reducing conditions shows the presence
of a protein above 35 kDa that corresponds to the calculated molecular mass of 38 kDa for
89

CytB5-rHNE (Figure 3.6a); however, many other proteins of lower molecular mass also appear
in the sample, likely products of incomplete translation or protein degradation that co-purify with
the activable enzyme as a consequence of the N-terminal location of the 6xHis tag (Figure 3.6a).
After overnight treatment with EP, the same sample displays a prominent band at 25 kDa (Figure
3.6a), the calculated molecular mass of activated rHNE. Faint bands of varying molecular mass
in the activated rHNE sample likely correspond to inactive fragments cut by EP or HNE (Figure
3.6a). Purified, native HNE is a mixture of three isoforms with different glycosylation patterns
that migrate between about 25 – 30 kDa (Figure 3.5a)74,75. The native HNE sample also displays
prominent bands between 10 – 15 kDa due to limited autolysis, similar to commercial
preparations from whole blood (http://www.athensresearch.com/products/enzymes-andinhibitors/elastase-human-neutrophil).
Western blotting with a rabbit anti-HNE primary polyclonal antibody and HRPconjugated goat anti-rabbit IgG secondary antibody labeled both native HNE and activated rHNE
at ~25 kDa (Figure 3.6b); however, the CytB5-rHNE zymogen was not detected. The 10 kDa
band that appears in the CytB5-rHNE sample on the blot (Figure 3.6b) is likely due to nonspecific binding. In the native HNE sample, an additional band below 15 kDa is also labeled on
the Western blot (Figure 3.5b) and corresponds to an autolytic fragment that is also seen in
commercial preparations from whole blood (http://www.abcam.com/Neutrophil-Elastaseprotein-Active-ab91099.html).
Attempts were made (not shown) to further purify the enzymes by ion exchange
chromatography as well as affinity chromatography on columns with immobilized inhibitors
basic pancreatic trypsin inhibitor (BPTI, Trasylol®) and secretory leukocyte proteinase inhibitor
(SLPI); however, these pursuits met with limited success. In the case of BPTI, a small amount of
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activated rHNE was recovered but most activity did not adsorb and the results were not
reproducible. HNE affinity for the SLPI affinity column was very strong and resulted in
complete adsorption of rHNE activity. This rHNE activity was never recovered successfully,
despite the use of various denaturants and chaotropic agents. Of these, 8 M urea released some
measurable activity from the column yet only about 20% of the original activity could be
accounted for; furthermore, 8 M urea did not reduce the activity of HNE. The further
purification of rhCatG has also been unsuccessful thus far.

Partial Purification and Activation: rHNE in K. lactis
Despite poor production with the K. lactis expression platform, CytB5-rHNE was
partially purified from K. lactis fermentation medium, but without the use of buffer exchange or
ultrafiltration. Recombinant protein was detectable in IMAC elution fractions by the presence of
410 nm peaks in the absorbance spectra, as in Figure 3.4a; however, absorbance at 280 nm was
obscured by excess imidazole. The intensity of 410 nm absorbance was very low (<0.06 units)
and indicative of poor recovery. Samples activated with varying amounts of EP (volumes listed,
concentration unknown) revealed the activation of rHNE as a function of time and the amount of
EP used (Figure 3.7). Based on the final maximum activity (Figure 3.7), only 100 ng of active
rHNE was recovered in the most active fraction and the total recovery was less than 1 µg.
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Figure 3.7: Activation of CytB5-rHNE Partially Purified by IMAC from K. lactis
Fermentation Medium. Identical 50 µL samples were treated with the indicated volumes of an
EP sample (concentration unknown) in a total reaction volume of 100 µL. After 4 hours
(yellow) and 24 hours (blue), samples were measured for activity with chromogenic MeO-SucAAPV-pNA. The results show that IMAC purified CytB5-rHNE from K. lactis is activated by
EP and that increasing amounts of EP reduced the amount of time needed for the fusion protein
to become fully active. Based on the maximum activity (~ 0.5 mA410/min), this 2 mL fraction
contains only about 100 ng of active rHNE (150 ng of activable CytB5-rHNE).

Extremely low levels of expression and inefficient IMAC recovery hindered the
expression of rHNE and rhCatG in K. lactis. Work with this yeast occurred prior to the more
successful efforts with P. pastoris; furthermore, limited experience with yeast fermentation
during the work with K. lactis may have contributed to the poor results of this expression
platform. The low level expression and purification of CytB5-rHNE from K. lactis, as well as
the accompanying 410 nm absorbance properties of the protein, encouraged the further pursuit of
this fusion construct design; however, the decision was made to change to the P. pastoris
platform due to the volume of research available, as well as the prior familiarity of the
investigators, for this system.
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The Utility of Cytochrome B5 Fusion Domains in Recombinant Protein Expression
The heme-bound CytB5 fusion protein expression in P. pastoris has several implications
that extend well beyond the specific expression of these two recombinant serine proteases.
First, the red coloration of the cells, concentrated media, adsorbed samples on resins, and
eluted fractions, significantly improves the processes of fermentation and purification through
the use of visual confirmation and characteristic absorbance spectrum patterns to follow protein
location and concentration. It is hypothetically possible, although as yet experimentally
unconfirmed, that, if used in conjunction with the constitutively active GAP transcriptional
promoter, transformant cells might even express sufficient CytB5-based coloration on agar
selection plates to facilitate the identification of “super-producing” clones through the use of
simple visual observation during the transformant selection process.
Second, the ratio of the intensities of 410 nm and 280 nm absorbance peaks, A410/A280,
can be used to evaluate the relative purity and concentration of a sample. In the case of the NSPs
expressed here, the A410 reflected not only full length protein but also heme-binding, partially
translated products and this is a consequence of the use of an N-terminal 6xHis tag. With the use
of a C-terminal tag or other purification strategy designed to recover only full-length
recombinant proteins, the A410 would more accurately reflect the concentration. The molar
extinction coefficient of heme-bound CytB5 at 413 nm absorbance is 114,000 M-1 cm-1 for the
oxidized form and 185,000 M-1 cm-1 for the reduced form71. It is, however, important to note
that only a portion of the CytB5 fusion protein is in the heme-bound form71, which is necessary
for the 410 nm absorbance; consequently, the A410 cannot be used to directly quantify the total
concentration of fusion protein, only the heme-bound fraction.
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The ratio of A410/A280 does correlate with the relative level of purity of the sample. In
the case of CytB5-rHNE and CytB5-rhCatG, the most active fraction of rHNE (Figure 3.4a,
Fraction 6) has an A410/A280 ratio = 0.68 whereas the most active fraction of rhCatG (Figure
3.4b, Fraction 36) has an A410/A280 ratio = 0.13. This means that a larger percentage of the
protein in the rHNE fraction is heme-bound fusion protein than the percentage of rhCatG in its
equivalent fraction.
Third, the accumulation of dark red color in cells and culture media post-induction
relative to uninduced and untransformed cultures confirms that the two yeast species
manufacture hemin endogenously and that the induced overexpression of CytB5 fusion
constructs creates a “heme-sink” in the yeasts that is similar to results shown previously in E.
coli76. Centrifuged cell pellets from harvested P. pastoris fermentation cultures retained a dark
pink color that, even after extensive rinsing with buffers of high ionic strength, was only
extractable in a supernatant upon yeast cell lysis by French pressure cell disruption, sonication,
or manual glass-bead disruption methods; however, treatment of these cell extracts with EP did
not result in active rHNE or active rhCatG.
This suggests that the majority of CytB5-rHNE and CytB5-rhCatG proteins being
produced were retained by the cells and either misfolded or degraded. Recently, it has been
shown that P. pastoris expressing recombinant proteins under control of the methanol inducible
AOX1 promoter, but not the constitutively active GAP promoter, also exhibited secretory
limitations that resulted in accumulation of product in the ER and initiation of the ERAD
pathway77. Expression of the CytB5 NSP fusion proteins may prove more successful with the
use of the constitutive GAP promoter. If these proteins were more efficiently secreted, the
locations and intensities of the CytB5-based 410 nm absorbance peaks might reflect this.
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Conclusions
Further efforts are warranted in the recombinant expression of HNE and CatG based on
their successful secretion and partial purification from P. pastoris. Strains of this yeast have
recently been made available that express proteins with human glycosylation patterns (Pichia
GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichia-glycoswitch.php); consequently,
variants of rHNE and rhCatG should be attempted in which the native glycosylation sites have
not been disrupted. It is likely that the use of the constitutively active GAP transcriptional
promoter instead of AOX1 would improve the secretory capacity of the cells77 and this is
especially important in the case of CatG due to its low levels of expression. The procedures and
materials for purifying active rHNE and rhCatG must be revisited and optimized to improve both
the yield and purity of the recovered products.
The results of CytB5 fusion protein expression are encouraging with regard to the use of
CytB5 for the detection of protein production and purification using yeast expression platforms,
as has previously been demonstrated for E. coli71,72, and this method is worthy of further
application. The expression of rHNE and rhCatG would have been much more difficult without
observation of the 410 nm peak in the absorbance spectra because these enzymes require
enzymatic activation prior to detection and quantification based on activity. Absorbance maxima
at 280 nm are sufficient to follow total protein recovery during the purification process; however,
confirmation of protein location by the presence of a red color enabled the visual verification of
protein expression and optimization of protein purification.
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Materials and Methods
Molecular Cloning
The NCBI database was used as a source for the native amino acid sequences of HNE
(NCBI Ref. Seq. NP_001963.1) and CatG (NCBI Ref. Seq. NP_001902.1). The amino acid
sequence of the soluble heme-binding domain of R. norvegicus CytB5 (from NCBI Ref. Seq.
NP_071581.1) was identical to that previously used for recombinant expression in E. coli71. All
amino acid and gene sequences were analyzed and modified using the software Geneious® 6.1.4
(Biomatters, http://www.geneious.com). Custom genes were codon-optimized for expression in
P. pastoris and K. lactis and synthesized by GenScript, who provided the genes in pUC57
plasmids for subcloning. The CytB5 gene was flanked by 5’ XhoI and 3’ KpnI restriction sites
whereas both rHNE and rhCatG included 5' KpnI and 3’ NotI sites.
Standard techniques were used throughout the molecular cloning process. Briefly,
plasmids were treated with appropriate restriction enzymes (Thermo Scientific, Fermentas
FastDigest®) and digestion fragments were recovered from agarose gels using the Zymoclean™
gel DNA recovery kit (Zymo Research). The recovered inserts were ligated into the multiple
cloning sites (MCSs) of the target plasmids using Quick-Stick Ligase (Bioline) and transformed
into Z-Competent™ chemically competent DH5α E. coli (Zymo Research). Plasmid assembly
occurred in two stages. First, the CytB5 gene was inserted separately into both pPICzα A and
pKLAC1 expression plasmids using XhoI and KpnI restriction sites to position the inserted
sequence in the correct reading frame at the 3’ end of the sequence encoding α-mating factor and
the two plasmids were designated as pPICzα-CytB5 and pKLAC1-CytB5. Second, the rHNE
and rhCatG genes were inserted similarly into the MCSs of pPICzα-CytB5 and pKLAC1-CytB5
with the restriction sites KpnI and NotI. The sizes of all plasmid inserts were verified by PCR to
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amplify the MCS contents using primers provided with the yeast expression kits, GoTAQ® AllIn-One Master Mix DNA Polymerase (Promega) and its protocols.

Transformation of P. pastoris
The P. pastoris transformation protocol was adapted from instructions for the
EastSelect™ Pichia Expression Kit (Life Technologies). The plasmids, designated pPICzαCytB5-rHNE and pPICzα-CytB5-rhCatG, were treated with the restriction enzyme BstXI to
generate linearized insertion cassettes for electroporation. These cassettes were recovered with a
DNA cleanup kit (Zymo) and further concentrated by ethanol precipitation. X-33 P. pastoris
cultures were prepared for and transformed by electroporation as prescribed by Life
Technologies, using a cuvette with a 2 mm gap and a BTX ECM 600 electroporation system
with settings at 1.5 kV and 186 Ω to result in a 7.5 msec pulse length. Transformants were
selected for resistance by growth at 30 °C on YPDS agar plates with ampicillin and Zeocin™
(100 µg/mL, each) and positive colonies were re-plated to fresh YPD agar plates, also containing
ampicillin and Zeocin™, and numbered for further screening.

Transformation of K. lactis
The chemical transformation of K. lactis used reagents and followed instructions
provided with the K. lactis Protein Expression Kit (New England Biolabs, NEB). The plasmids,
pKLAC1-CytB5-rHNE and pKLAC1-CytB5-rhCatG, were both linearized with the BstXI
restriction enzyme and recovered with a DNA clean up kit (Zymo). Chemically competent
GG799 K. lactis were thawed, treated with linearized DNA and a transformation reagent, and
subjected to treatment as per instructions. Transformed cells expressing the enzyme acetamidase

97

were selected for growth at 30 °C on nitrogen-free yeast carbon base (YCB) agar plates
containing 5 mM acetamide. Positive colonies were re-plated to YPD agar plates and numbered
for further screening.

Expression Screening
Culture Conditions. Numbered clones were grown under sterile conditions as either 2
mL liquid cultures in 12-well plates or 10 mL cultures in 50 ml conical tubes, depending on the
number of transformants available. P. pastoris were grown in synthetic minimal medium
(SMM) comprised of 10 g/L monosodium glutamate (MSG), 2.5 mg/L (NH4)2(SO4), 1.34% yeast
nitrogen base, >4 x 10-5% biotin, and 100 mm potassium phosphate at pH = 5.0 and containing
100 µg/mL of both ampicillin and Zeocin® (Life Technologies); furthermore, they were fed 1%
methanol every 24 hours and grown with orbital shaking at 28.5 °C for 4 days prior to harvest.
K. lactis were grown in SMM at pH = 7.0 containing 2% casamino acids and 100 µg/mL of
ampicillin. K. lactis were fed 1% galactose every 24 hours and grown with orbital shaking at
28.5 °C for 4 days prior to harvest. Culture supernatants were clarified by centrifugation and
retained, along with the separate cell pellet, for further analyses.
Enzyme Activation. Supernatants from screening cultures were adjusted to pH = 8.0 by
titration with 1 M Tris, pH = 9.0 and centrifuged to remove insoluble material. Samples were
treated with EP overnight at 37 °C prior to activity testing.
Activity Assays. All reported activity assays for HNE and CatG activity, regardless of
source, purity, or stage of analysis, follow this protocol. EP-treated samples were tested for the
enzymatic cleavage of chromogenic, synthetic peptide substrates. Methoxysuccinyl-AAPVpara-nitroanilide (MeO-Suc-AAPV-pNA; EMD Millipore Cat#454454) and the similar
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thiobenzyl ester substrate Suc-AAPV-SBzl (LifeTein custom synthesis) were used to detect HNE
activity; similarly, CatG activity was detected with Suc-AAPF-pNA(Sigma #S-7388) and SucAAPF-SBzl (LifeTein custom synthesis). Assays were conducted in 100 µL reaction volumes in
96-well microtiter plates and monitored over the course of 10 minutes for the accumulation of
410 nm absorbance indicating substrate cleavage. Each reaction was composed initially of 5 to
25 µL of activated sample with sufficient assay buffer containing 100 mM HEPES, 1 M NaCl,
10 % glycerol, 0.01 % Trition X-100, and 0.01 % NaN3 at pH = 8.0 to bring the total volume to
50 µL. Immediately prior to initiating the absorbance assay, 50 µL of substrate buffer made
from the assay buffer with 300 µM of the appropriate substrate were added to the reaction
mixture. Assays using the thiobenzyl ester substrates also contained 100 mM DTNB.
PCR Testing for Multicopy Transformants. Genomic DNA (gDNA) samples were
recovered from cell pellets by phenol/chloroform extraction and ethanol precipitation using
standard procedures78-81. The integrity of all gDNA samples was confirmed by gel
electrophoresis using the FlashGel cartridge system (Lonza) per its instructions. PCR for singleand multi- copy integrations were conducted using the procedure and integration primers
provided with the EasySelect™ Pichia Expression Kit (Life Technologies). PCR screening of K.
lactis used the procedure and primers provided with the K. lactis Protein Expression Kit (NEB).
All PCR used GoTAQ® All-In-One Master Mix DNA Polymerase (Promega) and its protocols.

Fermentation and Media Processing
All fermentations were conducted in a BioFlo 110 bioreactor (New Brunswick),
following its user’s manual, with a dissolved oxygen sensor (Mettler-Toledo) and a pH probe to
monitor culture conditions. Cultures were grown following the guidelines of the Pichia
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Fermentation Process Guidelines by Life Technologies and modifying feed and media
formulations as needed. Several growth media were tried for P. pastoris and K. lactis based on
the formulae for basic salts medium (BSM) recommended by the Life Technologies guidelines
and FM2282 and using their respective trace element supplements, PTM1 and PTM4. The most
successful medium formulation was found to be a variation of BSM supplemented with PTM4 to
reduce the formation of insoluble salts. This BSM variant included the addition of 10 g/L MSG
and a supplementary vitamins mix that was made as a 100x concentrate containing 0.1 g/L LHis-HCl, 0.2 g/L DL-Met, 0.2 g/L DL-Trp, 0.0002 g/L biotin, 0.0002 g/L folic acid, 0.2 g/L
inositol, 0.04 g/L niacin, 0.02 g/L p-aminobenzoic acid, 0.04 g/L pyridoxine HCl, 0.02 g/L
riboflavin, 0.04 g/L thiamine HCl, 0.04 g/L calcium pantothenate, 10 g/L CaCl2.
Upon harvest, fermentation media supernatants were clarified by centrifugation followed
by filtration through glass fiber pre-filters (Millipore Cat#AP2004200) and 0.45 µm filters (Pall
P/N 60173). Clarified P. pastoris broth volumes were reduced by ultrafiltration with 10 kDa
molecular weight cut-off (MWCO) tangential flow filtration cartridges (Sartorius Vivaflow50
P/N VF05P0). During ultrafiltration, the media were flushed extensively with IMAC binding
buffer containing 25 mM sodium phosphate and 300 mM NaCl at pH = 8.0. K. lactis
fermentation supernatants were not subject to ultrafiltration.

Immobilized Metal Affinity Chromatography
IMAC used either His-Bind® Resin (EMD Millipore) or Profinity™ IMAC Resin (BioRad). All stripping, equilibration, loading, washing, and elution buffers contained 25 mM
sodium phosphate and 300 mM NaCl at pH = 8.0. The metal ion stripping buffer contained 100
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mM EDTA; the equilibration and loading buffers contained no additional components; the
washing buffer contained 5 mM imidazole; the elution buffer contained 20 mM imidazole.

SDS-PAGE and Western Blotting
NuPAGE® Bis-Tris polyacrylamide gels (Life Technologies) were run using MOPSSDS running buffer and stained with Coomassie blue stain (SimplyBlue™; Life Technologies).
For Western blotting, gels were run as above and blotted to PVDF by semi-dry transfer.
Membranes were blocked with 1% BSA in TBST. The primary antibody was polyclonal rabbit
anti-HNE (Athens Research) and the secondary antibody was polyclonal goat anti-rabbit HRPconjugate (Pierce).

Spectrophotometry
All protein absorbance values and spectra were read on a Biotek PowerWave™ XS2
plate reader using Corning Half Area 96 well plates P/N 3679. For DNA samples,
concentrations were determined by measuring absorbance in a NanoVue™ spectrophotometer
(GE).
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Abstract
C-reactive protein (CRP) is an acute phase protein that binds phosphocholine (PCh) and
the complement protein C1q. CRP in known to bind oxidized LDL (oxLDL) under acidic
conditions and the E42Q amino acid substitution improves oxLDL binding at physiological pH.
Recombinant wild-type human CRP (rCRP) and the rCRP E42Q substitution variant were
expressed in the yeast Pichia pastoris under methanol induction, yielding correctly folded and
functional pentameric proteins in the culture media. For rCRP, 3.7 mg/L were expressed when
grown in synthetic minimal medium in baffled shaker flasks while the rCRP E42Q variant
expressed 1.7 mg/L and these proteins were purified by PCh affinity chromatography. Both
proteins were shown to bind to immobilized PCh like native human CRP (hCRP); however,
rCRP was expressed in two forms, one with the correct monomeric molecular mass of ~25 kDa
and a second, slightly larger monomeric form, as shown by SDS-PAGE and Western blot with a
CRP-specific antibody. A later SDS-PAGE only showed a single band for rCRP purified by PCh
affinity. The two forms could not be separated by PCh affinity chromatography, ion-exchange
chromatography, or gel-filtration chromatography. The source of the extra mass has not been
determined.

111

Introduction
C-reactive protein (CRP) expression by hepatocytes increases rapidly early in the acute
phase response of innate immunity, with plasma levels increasing as much as 1000-fold in
response to acute inflammatory stimuli1. CRP was discovered in 19302 for its ability to
precipitate C-lipopolysaccharide present on the cell wall of Streptococcus pneumonia. Later,
phosphocholine (PCh) was identified as the component of C-lipopolysaccharide that serves as
the ligand for CRP3. PCh-associated CRP binds complement component C1q and allows CRP to
activate the classical complement activation cascade, although only C1-C4 are activated, without
activation of the later complement components C5-C91,4. CRP has also been shown to have
other potential binding partners, including chromatin, fibronectin, histones, laminin,
phosphoethanolamine, ribonuclear proteins, oxidized LDL (oxLDL), and the oxLDL receptor
LOX-15-9.
CRP is a member of the pentraxin family of acute phase pattern recognition receptors,
characterized by a homopentameric functional form. Identical monomers form a ring primarily
via electrostatic surface interactions between subunits. One side of the ring, the recognition face,
contains five calcium-dependent PCh binding sites, one on each subunit4. The other face, the
effector face, binds the globular head of complement component C1q, which spans the central
pore of CRP10; furthermore, the binding of CRP with immunoglobulin Fcγ receptors11,12 is also
thought to occur on the effector face1.
Patients with chronically elevated CRP levels have greater risk of diabetes13,14,
atherosclerosis15-20, and cardiovascular disease21-24. CRP is frequently used as a clinical marker
of inflammation and cardiovascular disease, as recommended by the American Heart Association
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and the Centers for Disease Control and Prevention25-27. CRP displays both pro-inflammatory
and anti-inflammatory8,11,28-30 activities whose net in vivo effects may depend on the context.
CRP has been shown to bind oxLDL under acidic conditions20,31,32 and the single residue
variant CRP E42Q also binds oxLDL at physiological pH9, likely by relaxing the interface
between the CRP subunits to improve the flexibility of the pentamer. Wild type and substitution
variants of CRP have been expressed as recombinant proteins in several expression systems
including E. coli, Leishmania tarentolae, Trichoplusia ni, and the yeast Pichia pastoris33-36.
CRP recently expressed in P. pastoris was found to contain the additional amino acid sequence
EAEA at the N-terminus36 because these amino acids were used to separate the kexin cleavage
site (KR) from the CRP N-terminus. These extra amino acids are not always completely
removed by the Ste13 dipeptidyl peptidase in P. pastoris following cleavage by kexin. While the
additional N-terminal amino acids did not seem to affect its function, the expression of wild-type
CRP, without added amino acids, in P. pastoris would provide a robust source of recombinant
protein that is structurally and functionally identical to the native human pentamer and an easier
method for producing variants.
For further study regarding the binding of CRP to oxLDL, both recombinant wild type
CRP (rCRP) and the single amino acid variant rCRP E42Q were expressed as secreted proteins
in P. pastoris, quantified by ELISA, and tested for PCh affinity. Both proteins formed
pentamers, as evinced by the ability to bind PCh like the native human CRP (hCRP) pentamer.
Wild type rCRP was further analyzed by SDS-PAGE and Western blot and it was found in two
monomeric forms of distinct molecular mass. Despite further purification efforts with anion
exchange chromatography and gel filtration, the two forms of wild type rCRP could not be
separated and this indicates that these two rCRP monomer types associated randomly into
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pentamers. The problem could be unique to the transformant clone that was selected for
expression or due to the culture conditions during expression; however, further studies are
required to resolve this issue.

Results
Protein Engineering and Molecular Cloning
Amino acid sequences for mature hCRP (NCBI Ref. Seq. NP_000558.2) and the CRP
E42Q single residue substitution variant were used, without further modification, to generate
synthetic cDNAs codon optimized for expression in the yeast P. pastoris. The yeast were
transformed with pPICzα A plasmids under transcriptional regulation of the methanol-inducible
AOX1 promoter and directed for secretion by the α-mating factor secretion signal sequence that
is removed by kexin during secretion. The kexin cleavage sequence, KR, is adjacent to the Nterminus of each CRP sequence, with no intervening residues (Figure 4.1)

Figure 4.1: Primary Structure of rCRP Construct with α-Mating Factor. The amino acid
sequence for rCRP (Black) with the α-mating factor secretion signal (Red) connected to the Nterminus of mature CRP by the kexin cleavage sequence KR~ (Blue), where “~” represents the
site of kexin mediated proteolysis. The substitution of Glu 42 (Green) with Gln 42 is the only
difference in the sequence of rCRP E42Q and these proteins contain no other modifications. In
the genes for both constructs, two stop codons (not shown) immediately follow the codon for the
C-terminal Pro 206.
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The codon-optimized sequences for both constructs were cloned into the pPICzα A
expression plasmid for P. pastoris, under control of the repressible, methanol-inducible
transcriptional promoter AOX1. These plasmids were used to transform the X-33 strain of P.
pastoris and positive transformants were selected by Zeocin® resistance for further screening.

Transformant Screening
Transformant clones of both protein variants were screened for best production using 2
mL cultures grown in synthetic minimal medium (SMM) in 12-well microtiter plates. These
cultures were grown for four days with methanol induction prior to harvest. Upon harvest by
centrifugation, the wet cell pellet weights (WCW, g/L) were measured for all cultures. CRP
production levels in culture supernatants were quantified (µg/L) by sandwich ELISA with a
polyclonal rabbit anti-human CRP IgG as the capture antibody, the mouse monoclonal anti-CRP
antibody HD2.4 for detection, and an HRP-conjugated goat anti-mouse secondary antibody for
chemiluminescence. The ELISA results were normalized to the WCW measurements to
determine ratios of production/cell mass, in units of µg protein/g WCW. These values were
analyzed to find the cultures expressing the most protein/cell mass. Of 47 clones screened for
each construct, four were selected for further analyses.
For the narrower pool of eight transformants (two sets of four clones), 10 mL cultures
were grown, inoculated to equal starting optical densities, OD600 = 1.0, in 50 mL conical tubes
in SMM with 1% methanol and fed 1% methanol each day for four days. These cultures were
analyzed again, as above, to isolate the most productive clone for each product.
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Protein Expression
The best producing clones were scaled up to 300 mL volumes of media in baffled flasks.
Various growth media based on recipes for BMMY and SMM were employed in efforts to
improve expression and secretion. The formulae experimented with these parameters:
temperature, pH, Ca2+ content, ionic strength, phosphate source (potassium orthophosphate or
sodium hexametaphosphate), culture volume (up to a 5 L scale in bioreactor fermentations),
induction phase length, methanol concentration, and induction co-feeding with glycerol or
sorbitol. Both BMMY-based and SMM-based media performed similarly; however, SMM
media were preferred for the improved regulation of culture conditions that they afford. The best
expression results were 3.7 mg/L of rCRP and 1.7 mg/L of rCRP E42Q, both achieved in normal
SMM at pH = 5.0 and buffered with potassium phosphate. These cultures were fed 1% methanol
each day for four days in 1 L baffled shaking flasks no more than 1/3 full with broth at 28.5 °C.
Glycerol and sorbitol co-feed attempts did not improve yields of either CRP construct;
furthermore, production was markedly reduced by glycerol (a known repressor of the AOX1
promoter).

PCh Binding Assays
Expression media for both recombinant variants were tested for binding to immobilized
PCh. These assays were performed similar to the sandwich ELISA; however, the polyclonal
rabbit anti-CRP antibody was replaced by immobilized PCh-BSA for CRP capture. Serial
dilutions of rCRP culture growth media displayed binding to PCh-BSA that was dependent on
Ca2+ and inhibited with EDTA (Figure 4.2a). PCh-BSA affinity was also dependent on either the
rCRP or rCRP E42Q concentration with results matching the behavior of the native human
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pentamer across the same concentration range (Figure 4.2b). These assays show that both
recombinant variants were secreted as stable pentamers because monomeric CRP has a
significantly lower affinity for PCh-BSA32. Both variants could also be recovered from culture
media by PCh-agarose affinity chromatography; however, problems emerged during the
purification process. Low levels of protein expression and the heavy formation of insoluble
phosphate salts in culture supernatants during purification led to reformulation of the growth
conditions and media. The best results were achieved with SMM at pH = 6 with 100 mM
potassium phosphate and fed 1% methanol daily for four days. At lower pH, CRP is more likely
to stick to other things and many previous cultures had been grown at pH = 5. Increasing the pH
caused the formation of insoluble phosphates; consequently, the clarified culture supernatants
were adjusted to pH = 8 followed by centrifugation and filtration to precipitate and remove as
much insoluble phosphate as possible. The E42Q variant was not further characterized and all
subsequent work focused on the production and purification of wild type rCRP, as shown below.
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Figure 4.2: PCh Binding Assays. For PCh binding assays, microtiter plate wells with
immobilized PCh-BSA were used to capture CRP from culture medium. Adsorbed CRP was
then detected with the monoclonal mouse anti-CRP antibody HD2.4 and an HRP-conjugated
goat anti-mouse secondary antibody. (A) Serial dilutions of culture medium showed binding of
rCRP to PCh-BSA in the presence of Ca2+ and the sequestration of Ca2+ with EDTA significantly
reduced this affinity, consistent with the known behavior of native hCRP. (B) The binding of
rCRP and rCRP E42Q to PCh occurred in a concentration-dependent manner identical to the
behavior of native hCRP. This confirms that rCRP and rCRP E42Q are expressed and secreted
as functional pentamers because the PCh binding affinity of monomeric CRP is significantly
weaker32.

Initial Purification and SDS-PAGE
Wild type rCRP was recovered from culture medium by immobilized PCh affinity
chromatography. Following this single-step purification, samples were analyzed by SDS-PAGE
(4% - 20%) under reducing conditions (Figure 4.3a). Although hCRP migrated as a single band
at the correct molecular weight, rCRP migrated as two bands (Figure 4.3a). The more prominent
band, of lower molecular mass, migrated at the same molecular weight as native protein;
however, the less prominent band has an apparent molecular mass of ~1 kDa greater than hCRP

118

(Figure 4.3a). A later, separate SDS-PAGE (12%) under reducing conditions (Figure 4.3b) did
not reveal the contaminant band in rCRP, although this may be due to overloading.

Figure 4.3: SDS-PAGE of PCh-Affinity Purified rCRP. (A) A 4% - 20% SDS-PAGE, under
reducing conditions, compares hCRP with rCRP upon single-step purification by affinity for
PCh. The rCRP migrates as two bands of distinct molecular mass, unlike the expected single
band of ~25 kDa, as shown for hCRP. The band of lower mass migrates like hCRP; however, a
second band of higher mass also appears approximately 1 kDa above. The band of larger mass
represents approximately 20% of the total protein in the sample, estimated by densitometry. (B)
In a separate reducing gel (12% SDS-PAGE), rCRP and hCRP both migrate at ~25 kDa,
although the second band appearing in (A) may be obscured in the broader band in (B).
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Further Purification
Because a second band was initially found to co-purify with rCRP based on PCh affinity,
further attempts were made to separate these two proteins by a three step process. First, rCRP
was purified by PCh (Figure 4.4a), as above. Second, PCh-purified rCRP was further purified by
anion exchange (Figure 4.4b). Third, the dual-purified sample was separated by gel filtration
(Figure 4.4c). Sample recovery data chronicles each stage of purification (Table 4.1).

Figure 4.4: Three Step Purification of rCRP. (A) An elution profile for purification of rCRP
by PCh affinity chromatography. Fraction volumes were 500 µL and fractions 13 – 28 were
pooled (5.5 mL) for subsequent steps. (B) This pooled sample was further purified by anion
exchange chromatography, which eluted as a single peak and focused the protein into a smaller
elution volume (2 mL pooled). (C) The anion exchange elution pool was separated by gel
filtration and eluted as a single major peak.
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Table 4.1: Three Step Purification of rCRP

SMM (PCh Input)
PCh Recovery
Anion Exchange Input
Anion Exchange Recovery
Gel Filtration Input
Gel Filtration Recovery

Total rCRP
(mg)
2.14
1

rCRP Concentration
(µg/mL)
3.2
200

0.885

200

0.573

287
1370
70

0.48
0.147

Yield (% of Input)

46.7
64.7
30.6

At each step of the purification, samples were collected for analysis by SDS-PAGE, with
each sample loaded in 1 µg and 5 µg quantities (Figure 4.5). PCh-purified rCRP, both with and
without EDTA, migrated with the same pattern as before; furthermore, the two bands failed to
separate at any stage of purification (Figure 4.5).

Figure 4.5: SDS-PAGE of Three Step rCRP Purification. Samples from each step of the
three-stage purification of rCRP are shown in comparison to hCRP. In each step, the two bands
fail to separate and the purity was never improved beyond the single-step PCh affinity
purification. The band of larger mass represents approximately 20% of the total protein in the
sample.
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Purified hCRP and rCRP were analyzed by Western blotting (Figure 4.6). Both were
labeled by the polyclonal rabbit anti-CRP primary antibody and heavy sample loading shows
some CRP degradation products in both sample types (Figure 4.6). Of particular importance,
both bands of the purified rCRP are labeled by the antibodies, indicating that the band with
~1 kDa more mass is likely an modified form of the protein (Figure 4.6).

Figure 4.6: Western Blot of hCRP and rCRP. Purified hCRP and rCRP samples of 75 ng,
150 ng, and 300 ng were loaded, as indicated. The PVDF membrane was probed with the
polyclonal rabbit anti-CRP primary antibody and an HRP-conjugated donkey anti-rabbit
secondary antibody. For both hCRP and rCRP, some degradation products can be seen. Both of
the bands that appear on the SDS-PAGE for the purified rCRP samples are labeled by the antiCRP antibodies on the Western blot, indicating that the band of larger molecular mass may be a
modified version of the correctly expressed protein.

122

Discussion
Both recombinant CRP variants were present as functional pentamers in the culture
supernatant. This was confirmed by the binding of the proteins to immobilized PCh-BSA in a
manner dependent on the concentrations of Ca2+ and CRP (Figure 4.2). The successful
expression of functional rCRP and rCRP E42Q in P. pastoris provides a useful source for
producing these proteins efficiently in large quantities. This expression platform may provide
further use for the production of other CRP variants as well. The presence of a second band of
protein that co-purified with rCRP provides a puzzle that has not yet been solved. Because later
SDS-PAGE of samples purified by PCh (Figure 4.3b) did not reveal the presence of this band, it
may be due to an unknown experimental effect or changes in growth conditions during protein
production. Examination of other transformed clones may reveal that the second band is
anomalous exclusively to the selected clone.
If the second band truly does co-purify with rCRP and is not an artifact, then further
analyses are required to determine the source of this modification. It is possible that a portion of
the protein was post-translationally modified in some unforeseen manner; however, no
glycosylation sites are present. An SDS-PAGE (not shown) was treated with a stain specific for
phosphorylated proteins and found that both hCRP and rCRP stained to the same extent. Mass
spectrometry may illuminate this issue.
Although much exploration of culture media and growth conditions failed to improve the
expression of these proteins beyond 4 mg/L, significant experience has been gained during this
process regarding the production of recombinant proteins in the yeast P. pastoris. With further
attempts, it is anticipated that bioreactor-based yeast fermentation may yield improved results
relative to those previously seen for the expression of CRP. Finally, although the synthetic genes

123

used for rCRP and rCRP E42Q were produced by two different companies using different
optimization algorithms the expression levels did not differ significantly.

Materials and Methods
Molecular Cloning and Yeast Transformation
The amino acid sequence for hCRP was taken from the NCBI database (NCBI Ref. Seq.
NP_000558.2). Codon-optimized gene sequences were optimized and synthesized by DNA2.0
(rCRP E42Q) and by GenScript (rCRP) and provided with 5’ XhoI and 3’ NotI in the pUC57
subcloning vector. The coding sequence was cloned into the pPICzα A P. pastoris expression
plasmid (Life Technologies) using standard molecular cloning techniques, as described in the
EasySelect ™ Pichia Expression Kit (Life Technologies). The restriction enzymes were
FastDigest® enzymes (Thermo Scientific). Digestion fragments were separated by agarose gel
electrophoresis and gel extraction (Zymo). Protein-coding inserts were ligated into pPICzα A
with Quick-Stick Ligase (Bioline) and the assembled plasmids were propagated in ZCompetent™ DH5α E. coli (Zymo) and transformed E. coli were screened for Zeocin™
resistance.
X-33 P. pastoris were transformed with linearized expression plasmids by
electroporation using the protocol in the EasySelect™ Pichia Expression Kit (Life
Technologies). Electroporation was conducted using cuvettes with a 2 mm gap in a BTX ECM
600 electroporation system set at 1.5 kV and 186 Ω with an approximate pulse length of
7.5 msec. Transformants were grown at 30 °C on YPDS agar plates containing 100 µg/mL of
Zeocin™ for transformant selection and 100 µg/mL of ampicillin to prevent bacterial
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contamination. After three days, individual colonies were plated to fresh YPD agar plates (with
the same antibiotics) and numbered.

Transformant Screening
Numbered clones were grown in 2 mL cultures in 12-well plates in synthetic minimal
medium (SMM) comprised of 10 g/L monosodium glutamate (MSG), 2.5 mg/L (NH4)2(SO4),
1.34% yeast nitrogen base, >4 x 10-5% biotin, and 100 mm potassium phosphate at pH = 5.0 and
containing 100 µg/mL of both ampicillin and Zeocin® (Life Technologies). The medium was
supplemented with 1% methanol and an additional 0.5% methanol was added each day for four
days. After four days, the cultures were harvested and the wet cell pellet weights (WCW) were
determined. Culture supernatants were clarified by centrifugation and screened by ELISA (see
below) for the presence of CRP. The ELISA results for CRP concentration (µg/mL) were
normalized by dividing by the WCW (mg/mL) to determine production efficiency (µg
protein/mg WCW). The four most productive clones of rCRP and of rCRP E42Q (eight total
clones) were identified and further screened for production in larger volumes.
In the second phase of colony screening, the most productive clones were all growth from
the same starting density (OD600 = 1.0) in SMM containing 1% methanol and fed 1% methanol
every day for four days. These cultures were grown in 10 ml volumes in 50 ml sterile conical
tubes with shaking at 30 °C. These clones were analyzed as described above for the 2 mL
cultures.
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ELISA
Sandwich-type ELISA analyses quantified recombinant protein samples relative to a
standard curve following the protocol previously published for quantification of CRP37.
Microtiter plate wells were treated with 100 µL of polyclonal rabbit anti-human CRP IgG
(Sigma) that was diluted 1:1000 in TBS, pH = 7.2. After 2 hours of incubation at room
temperature, the antibody was aspirated and the wells were blocked with TBS + 5 g/L gelatin at
room temperature for 45 minutes. After the blocking solution was removed, diluted samples
were added to the wells, with a series of samples of known concentration of hCRP to create a
standard curve. After 2 hours of incubation at 37 °C, the samples were removed and the wells
were washed three times with ELISA buffer (TBS + 0.1% gelatin + 0.02% Tween-20). A 100
µL aliquot of the monoclonal mouse anti-CRP antibody HD2.4 (0.5 µg/mL) was then added to
each well, followed by incubation for 1 hour at 37 °C. After the wells were washed again three
times with ELISA buffer, 100 µL of 1:1000 diluted HRP-labeled goat anti-mouse IgG (GE
Healthcare) was added and left to incubate for 1 hour at 37 °C. After a final round of three
washes with ELISA buffer, the HRP substrate was added. After a 10 minute incubation, the
absorbance values were measured at λ = 405 nm.

Protein Expression
Expression cultures were grown with methanol in 300 mL broth volumes in 1 L baffled
flasks with orbital shaking at 30 °C; similarly, starter cultures were grown with glycerol in 50100 mL volumes in 250 mL baffled flasks. The growth media BMGY and BMMY, described in
the EasySelect™ Pichia Expression Kit, contain 1% yeast extract, 2% peptone, 100 mM
potassium phosphate (pH = 6.0), 1.34% YNB, 4 x 10-5% biotin, and either 1% - 2% glycerol
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(BMGY) or 0.5% - 1% methanol (BMMY). Synthetic minimal media (SMM) contained 10 g/L
monosodium glutamate, 2.5 g/L (NH4)2SO4, 100 mM KH2PO4 (pH = 5.0), 4 x 10-5% biotin,
1.34% YNB, and either 2% glycerol or 0.5% - 1% methanol. Multiple modifications of the
SMM formula were attempted.
In some media formulations, potassium phosphate was replaced with sodium
hexametaphosphate (SHMP) to reduce precipitation; although, SHMP was found to be a poor pH
buffer. Some cultures received 0.1% - 0.5% glycerol or 0.5% - 1% sorbitol co-feeds with
methanol during the induction phase; however, these co-feeds did not improve expression. In
many cultures, solutions of vitamins and minerals were prepared in the lab as a substitute for
commercial YNB; however, these solutions were compositionally identical to YNB and did not
improve culture growth or protein expression in comparison. In addition to the pH values listed
above, cultures were also grown under other conditions between 4.5 ≤ pH ≤ 7.0. Some formulae
were supplemented with 2% Casamino acids to limit extracellular proteolysis of the protein
products. Despite multiple attempts with a range of media formulations, the standard SMM
medium was preferred due to composition control (relative to BMMG and BMGY) and formula
simplicity (relative to other SMM formulations).

Purification
All purification processes follow procedures previously described31,38. Affinity
chromatography with PCh-conjugated Sepharose (Pierce) used a loading buffer of borate
buffered saline (BBS) (100 mM boric acid, 25 mM tetra-sodium borate, 225 mM NaCl, pH =
8.35) with 3 mM CaCl2 and an elution buffer of BBS with 10 mM EDTA. Eluted samples were
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dialyzed overnight against Mono Q buffer A (20 mM Tris, 150 mM NaCl, 0.1 mM EDTA, pH =
7.8).
Anion exchange chromatography used a Mono Q column (5/50 GL Pharmacia #17-516601) equilibrated with Mono Q buffer A and connected to a BioRad Biologic Duo Flow Protein
Purification System. After loading at 0.5 mL/min, proteins were eluted with a buffer gradient
from 150 mM NaCl (Mono Q buffer A) to 1 M NaCl (Mono Q buffer B).
HPLC gel filtration was performed using Superose 12 (10/300 GL Pharmacia #17-517301) with a bed volume of 24 mL in a 10 x 300 mm column connected to a BioRad Biologic Duo
Flow Protein Purification System. The sample was prepared by concentrating 1.8 mL of Mono
Q purified CRP to a final volume of 250 µL containing 480 µg of protein that was injected into
the column. Purified proteins were stored in TBS with 0.1 mM CaCl2.

SDS-PAGE and Western Blotting
The 4%-20% SDS-PAGE gels were manually cast and run in Tris-Glycine buffer (25
mM Tris, 192 mM glycine, 0.1% SDS, pH = 8.3). These gels were run at 80 – 100 V until the
samples entered the stacking gel and then at 180 V for 4 hours. The 12% SDS-PAGE used a
precast NuPAGE® Bis-Tris acrylamide gel (Life Technologies) in MOPS-SDS running buffer.
Gels were stained with Coomassie blue stain.
Western blotting was performed by semi-dry transfer for 35 minutes at 25 V with PVDF
in a Tris-glycine western transfer buffer (39 mM glycine, 48 mM Tris, 0.03% SDS, 20%
methanol, pH = 8.9). The membrane was blocked with 5% powdered milk in TBS overnight at 4
°C. The primary antibody was rabbit polyclonal anti-CRP and the secondary antibody was HRPconjugated donkey anti-rabbit IgG. Results were visualized by ECL chemiluminescence.
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CHAPTER 5
DISCUSSION AND CONCLUSION

Yeast Recombinant Expression Systems
The yeast Pichia pastoris served as a suitable host for the transgenic expression of
recombinant variants of the human proteins enteropeptidase, cathepsin G, neutrophil elastase,
and C-reactive protein. Although the results of protein expression in Kluyveromyces lactis were
less successful, many of the issues at that time resulted from lack of user experience and limited
availability of literature on the platform. These recombinant protein expression studies yielded
much experience regarding the fermentation of yeasts; however, the K. lactis constructs were
abandoned in favor of the more familiar P. pastoris before much success was achieved. The
results of this work should not be taken to imply that the K. lactis system suffers from any
inferiority as a recombinant expression system; contrarily, K. lactis shares many of the
advantages of P. pastoris, as already discussed.

Promoter Selection, Codon Optimization, and Custom Gene Synthesis
While the AOX1 methanol-inducible promoter provided strict control over protein
production in P. pastoris, future work to express variants of these enzymes should use the
constitutively active GAP promoter, based on recent research that indicates improved secretory
capacity with GAP (Love et al. 2012). Levels of recombinant protein expression for EP, CatG,
HNE, and CRP never exceeded 5 mg/L; however, Life Technologies reports much higher
production yields for P. pastoris. The relatively low yields that were obtained may have been
the result of poor secretion and not poor production. The finding that red color accumulated
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inside P. pastoris during the expression of CytB5-rhCatG and CytB5-rHNE suggests that much
of the product was not secreted and may have led to intracellular protein degradation, as has been
shown elsewhere to occur with use of the AOX1 promoter in P. pastoris (Love et al. 2012).
Expression of these proteins under control of the GAP promoter may alleviate this problem.
It is impossible to say if codon optimization of the gene sequences had a significant
impact on levels of protein expression without making a comparison to expression results for
nonoptimized genes encoding the same protein. Even then, confounding factors such as
insertion cassette copy number, variations in secretory capacity, and other clone-to-clone
variations have significant effects on protein expression levels that cannot always be predicted
and can significantly affect the evaluation of codon optimization. Indeed, screening of over 50
transformant clones often yields only 1 or 2 with significantly higher expression levels for which
the cause of improvement is unknown.
Custom gene synthesis was found to have many advantages for simplifying the process of
engineering recombinant proteins regardless of the usefulness of codon optimization. This
process made it easier to create the multisubunit CytB5 fusion constructs by eliminating the need
for multiple PCR steps. The disruption of numerous potential sites of glycosylation and kexin
cleavage was also performed without the need for PCR-based site-directed mutagenesis and
subcloning procedures.

Glycosylation and Cleavage Site Disruptions
The disruption of glycosylation sites in rEP, rhCatG, and rHNE did not appear to
adversely affect the enzymatic properties of any of these serine proteases; however, future
studies may require serine proteases with native human glycosylation. Recently, a new P.
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pastoris expression system has been developed that allows users to select from several patterns
of human glycosylation (Pichia GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichiaglycoswitch.php). Use of this system not only eliminates the need to disrupt glycosylation sites
but also allows recombinant production of proteins that more closely resemble their natural
counterparts. Future attempts to express recombinant human serine proteases in P. pastoris may
benefit from a humanized glycosylation pattern.
The decision to disrupt potential sites of kexin proteolysis may or may not have improved
protein expression. Because previous attempts to express CatG from the human cDNA had met
with only limited success, kexin proteolysis was proposed as a potential factor reducing
expression. It has been previously shown that high pI proteins like CatG do not express well in
P. pastoris (Boettner et al. 2007) and the high frequency of dibasic sequences certainly indicates
that kexin proteolysis may be a factor. With some genetic manipulation, a strain of P. pastoris
could be engineered by disruption of the KEX2 gene that would significantly reduce the
vulnerability of dibasic sequences to proteolysis during secreted expression. Although the
expression products would retain the α-mating factor after secretion, the use of an EP cleavage
site would enable removal of this N-terminal fusion domain without the need for kexin protease.

Thoughts on Arginine Content and Recombinant Protein Expression
Although it is possible that a prevalence of dibasic sequences predisposes a yeastsecreted recombinant protein to cleavage by kexin, at least 2 other possibilities may also be
responsible for the poor expression of high pI proteins, as proved to be the case with rhCatG.
First, proteins and peptides with high arginine content can have antimicrobial properties, as has
previously been shown for CatG (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991;
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Miyasaki et al. 1993; Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002). While
fermentation cultures of P. pastoris expressing CytB5-rhCatG did not display any signs of
impaired growth rates or increased cell death, it is possible that highly basic proteins may
interfere with intracellular function in other ways that could reduce production efficiency.
Second, an excess demand for Arg could surpass the ability of the yeast to supply charged ArgtRNAs, resulting in a higher incidence of premature ribosome disassembly and accumulation of
truncated protein products. This potential problem could be exacerbated by an overabundance of
one Arg codon in a codon-optimized sequence; however, careful regulation of protein production
rates by limiting methanol availability and temperature could also counteract this issue by
allowing the cells time to regenerate their supply of charged tRNAs. As mentioned previously,
absolute levels of tRNA abundance have not been characterized for P. pastoris and this
information would greatly enhance the current work on codon optimization for the improvement
of recombinant protein expression.

Enteropeptidase: Variations on a Theme
The recombinant expression of variants of hEPL proved very successful regarding the
manipulation of this enzyme’s high level of substrate specificity. While the reduced specificity
of the R96Q substitution variant was of academic value for confirming the role of this residue in
the extended substrate binding preferences of hEPL, the improved specificity conferred by the
Y174R substitution has practical value for reducing nonspecific cleavages by this highly specific
protease that is used in biotechnology to separate recombinant fusion protein domains. Although
it was not mentioned and no data was presented, studies with CatG indicated that the CatG
substrate Suc-AAPF-SBzl was cleaved by EPL, likely due to the geometry of the EPL S1
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specificity pocket, which appears to be large enough to accommodate the Phe residue of this
synthetic substrate. In an attempt to eliminate this undesirable activity, an EPL variant was
attempted in which the residue Gly 226 was replaced with Asp, in addition to the Y174R
substitution; however, this completely abolished the enzymatic activity of the protein, likely by
limiting the size of the S1 specificity pocket.
Despite the failure of the G226D substitution to improve, or even retain, substrate
specificity, further efforts to modify the extended binding site of EPL may yield further
improvements on specificity or even facilitate the custom design, based on other similar serine
proteases, of restriction proteases with novel substrate preferences. The chymotrypsin-like
serine protease granzyme B, for example, has a relatively strong preference for P1 Asp residues
due to the presence of Arg 226 in the base of its S1 specificity pocket. Because granzyme B and
EPL both share the same chymotrypsin-like tertiary structure, residues with the same number
share very similar positions regardless of the identity of the amino acid at the given position.
Although the substitution G226R in EPL would likely limit the size of the S1 specificity pocket
as was seen for G226D, the fundamental concept of altering the charge of this binding site could
completely change the substrate specificity.
In one particularly promising design, either substitution D189R or D189K could
completely convert the P1 preference of EPL from positively charged Lys or Arg to negatively
charged Asp or Glu. By itself, this change in substrate specificity would confer specificity for
any poly-Asp sequence; however, the exact site of proteolytic cleavage might be difficult to
control. By adding the substitutions R96D and K99D, the substrate specificity of hEPL could
theoretically be completely reversed from DDDDK~X to, for example, KKKKD~X. Although
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this may seem like an esoteric exercise, experimentation along these lines could result in novel
approaches to engineer customized substrate specificity for biotechnological purposes.

The Untold Story: Other Expression Attempts with rhCatG and rHNE
The recombinant expression of rhCatG and rHNE was subject to many difficulties and
multiple fusion partner domains were attempted prior to the successful results obtained with the
CytB5 soluble heme-binding domain. A table is provided that chronologically summarizes the
attempted constructs (Table 5.1), all of which failed to yield the desired results.

The first attempted fusion was human serum albumin (HSA), which is the most abundant
protein in blood plasma and displays a known affinity for the blue dye Cibacron Blue. Although
as much as 1.4 g/L of HSA has been expressed in P. pastoris (Kobayashi et al. 2000), this fusion
partner did not provide a suitable “carrier protein” to facilitate production of rhCatG or rHNE.
Because this was the first construct that was attempted, lack of positive results may have been
caused by limited user experience; however, many other issues have been encountered since then
that may have also contributed to the failure of the HSA fusion protein design.
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In an effort to improve the detection of fusion protein production, enhanced green
fluorescent protein (eGFP) was employed for its ease of detection, with an N-terminal 6xHis tag
for purification. All 6xHis tags employed in these designs were located at the N-terminus of the
secreted protein and this leads to the purification of truncated protein products and partial
degradation fragments. Because the nature of this study required the production of enzymes with
C-termini free of amino acid extensions, the more desirable C-terminal 6xHis tag could not be
used. Initial results with eGFP suggested that some protein was being produced by this method;
however, very little activity and virtually no green fluorescence could be detected in the culture
supernatant. Later analysis of yeast cells using fluorescence microscopy suggested that this
recombinant fusion protein may have been accumulating inside the cells, results that have since
been reinforced by the intracellular accumulation of red color in P. pastoris cells expressing
CytB5 fusion proteins.
The third recombinant fusion domain, rubredoxin, was the first attempt by this lab to
exploit a protein’s chromogenic properties for the detection of fusion constructs. Rubredoxin
binds iron atoms and displays an absorbance peak at λ = 410 nm; however, the extinction
coefficient of rubredoxin at 410 nm is only 5.5% that of CytB5 (Mitra et al. 2005). The
recombinant expression of rubredoxin chimeras, much like eGFP, only resulted in low yields of
enzymatic activity. Curiously, the culture supernatant did display a rusty brown color; however,
this color was a precipitate that settled upon centrifugation (15,000 – 21,000 x g).
The presence of the rusty brown precipitate was tantalizing because it had not been
observed with the previous fusion constructs. At this time, other chromogenic proteins were
evaluated as candidates and CytB5 was selected based on previous success with this fusion
domain in E. coli (Finn et al. 2005; Mitra et al. 2005). While this later proved to be the most
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successful attempt at expressing rhCatG and rHNE in P. pastoris, the CytB5 fusion construct
was at one time discarded due to difficulties with the 6xHis-IMAC purification process. Initial
results showed acceptable levels of protein expression for both enzymes; however, the proteins
did not adsorb well to IMAC resin charged with Ni2+, Co2+, or Cu2+.
After many attempts to improve IMAC purification yields for CytB5 fusion proteins, a
new approach was devised using the small ubiquitin-like modifier (SUMO) protein as a fusion
tag. Due to continued success with recombinant expression of EPL, 2 versions of the SUMO
fusion were constructed apiece for rhCatG and rHNE, one with the EPL cleavage linker sequence
DDDDK and another lacking this sequence, being activated instead by a protease specific to
SUMO. Neither of these constructs yielded significantly better production results than the
CytB5 fusion proteins. Activation with the SUMO protease was costly because, unlike EP L,
SUMO protease was not available from recombinant expression system in the lab.

Improving the Purification of CytB5-rhCatG and CytB5-rHNE
Fortunately, further research proved that the issues with 6xHis-IMAC purification of the
CytB5 were surmountable. Of particular note, many manufacturers’ protocols indicate that Tris
can be used as a suitable buffer, but that it can also impair 6xHis binding to IMAC resin. For the
purification of CytB5-rhCatG and CytB5-rHNE, Tris was found to interfere with this stage of the
purification process. In contrast, phosphate buffers were found to significantly improve protein
binding to IMAC. Also, as-yet unidentified components of spent P. pastoris fermentation media
seem to interfere with 6xHis-IMAC purification. While buffer exchange by membrane
ultrafiltration improved IMAC purification yields, these proteins were eluted under very low
concentrations of imidazole (20 – 50 mM) and were difficult to separate from other contaminants
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that dissociated from the column under the same imidazole concentrations. Future attempts to
improve the expression of rhCatG and rHNE by these methods should employ a deca-histidine
(10xHis) tag (or longer) for improved Ni2+ affinity because this may increase the concentration
of imidazole required to elute the protein of interest and could improve efforts to eliminate
contaminants.
The more significant difficulty that was encountered in the purification of rhCatG and
rHNE was the failure to recover these activated enzymes by affinity chromatography for basic
pancreatic trypsin inhibitor (BPTI, Trasylol®). Attempts to use secretory leukocyte proteinase
inhibitor (SLPI) in place of BPTI succeeded in adsorbing over 99% of active rHNE and native
HNE; however, the extremely tight binding interactions between HNE and SLPI proved very
difficult to break. Because BPTI has been used routinely in the purification of HNE and CatG in
the past (Baugh and Travis 1976), the efficiency of the BPTI column that was used is called into
question.
The BPTI columns used in these experiments were created by coupling BPTI to Nhydroxysuccinimide (NHS) reactive groups on the surface of an agarose support matrix (BioRad
Affi-Gel® 10). These NHS groups react with the side chain amino groups of Lys residues.
BPTI only contains 4 Lys residues; furthermore, 1 of these, Lys 15, is the P1 residue of the
active site of this reversible protease inhibitor. By coupling BPTI to NHS-agarose without first
blocking the active site residue Lys 15, a significant portion of the total BPTI bound to the resin
will be inactivated by the reaction of Lys 15 with NHS. To ensure that 100% of the BPTI
coupled to the column is active, the BPTI should first be equilibrated with excess acetylated
trypsin (Ac-trypsin) to block Lys 15. Ac-trypsin has no free amines available to react with NHSagarose; consequently, it will not couple to the resin. Because the BPTI-trypsin interaction is
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pH-dependent, BPTI can be coupled to NHS-agarose using the other Lys residues while Lys 15
is blocked with Ac-trypsin. This protease can then be eluted from the column by lowering the
pH.
It is proposed that the BPTI columns used during this work did not contain a high enough
concentration of functionally active BPTI to efficiently adsorb the low concentrations of rhCatG
and rHNE present in samples. BPTI affinity matrix prepared using Ac-trypsin, in the manner
described above, could circumvent this problem and drastically improve the purification of these
enzymes by the well-established method of BPTI affinity chromatography.

Learning to Fly: Lessons in Recombinant Yeast Fermentation
The single largest hurdle in the successful expression of large amounts of recombinant
proteins by yeast is the control and optimization of growth conditions. Bioreactor-based
fermentation methods are strongly recommended over methods that use baffled flasks because of
the increased level of control that bioreactors afford. Careful regulation of carbon, nitrogen,
oxygen, phosphate, pH, and temperature significantly improve efforts to optimize culture growth
conditions. When working with the methanol-inducible AOX1 promoter, it is very important to
properly regulate the concentration of methanol in solution to prevent its accumulation to toxic
levels. High-yield protein production also requires adequate supplies of oxygen that cannot
always be supplied by normal air. The pH of a yeast culture does not remain static throughout its
growth and cannot be held constant in baffled flasks. Bioreactors enable the careful regulation
and incremental modification of culture growth conditions and facilitate optimization of growth
media. Bioreactor-based fermentation of yeast, especially P. pastoris, is detailed in the
appendix.
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APPENDIX
ON BIOREACTOR BASED FERMENTATION OF YEAST

Recombinant yeast can be grown to high density in large volumes through the use of
bioreactor fermentation; furthermore, bioreactors facilitate monitoring and regulation of culture
conditions to provide an optimal growth environment for maximized protein production. Factors
such as temperature, acidity, and the bioavailability of several compounds can be controlled with
more accuracy and consistency in bioreactors than in the baffled flasks routinely used for culture
screening. Despite the additional factors to which the operator must attend, bioreactor
fermentation occurs on a time scale similar to that of the baffled flask platform, does not require
much additional effort, and results in higher yield of recombinant protein. Numerous review and
methods papers have been published (Stratton et al. 1998; Cereghino and Cregg 2000; Cereghino
et al. 2002; Zhang et al. 2002; Zhang et al. 2003; Plantz et al. 2006; Li et al. 2007; Bollok et al.
2009; Murasugi 2010; Ramón and Marín 2011; Bawa and Darby 2012; Bora 2012; Damasceno
et al. 2012).

Considerations for Media Formulation
Although complex media based on yeast extract and peptone are frequently used for
recombinant protein production in yeast, synthetic media provide many advantages, regardless of
the scale on which production will occur. Because they are derived from biological sources,
yeast extract and peptone are complex mixtures of poorly defined components; however,
synthetic media assembled from pure compounds provide a well-defined environment of
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specified composition and often result in improved culture growth rates and recombinant protein
production.
For the bioreactor fermentation of P. pastoris, the formulation prescribed by the Pichia
Fermentation Process Guidelines (Life Technologies), designated Basal Salts Medium (BSM)
and supplemented with PTM1 Trace Salts, is used most frequently and is based on the formulae
used during the early development of this recombinant expression platform (Siegel and Brierley
1989; Brierley et al. 1990), although variations on this recipe such as FM22 (Stratton et al. 1998;
Wang et al. 2005) with PTM4 (Stratton et al. 1998) are often used (Table A1). All synthetic
media must include bioavailable sources of carbon, oxygen, nitrogen, and phosphate in addition
to several other ions including especially calcium, magnesium, potassium, and sulfate (Siegel
and Brierley 1989). The sources of these components, their concentrations, and the method of
their assembly can have significant impact on fermentation results and must be considered in
detail.

Table A1: Fermentation Media Components
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Carbon Sources
The carbon sources made available to yeast during fermentation may or may not impact
the rate of protein production depending on the chosen transcriptional promoter. For P. pastoris,
the two promoters most frequently used to direct recombinant expression are the alcohol oxidase
1 (AOX1) promoter and the glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter. The
GAP promoter is constitutively active and not sensitive to environmental conditions; however,
the AOX1 promoter is repressed by several carbon sources and induced only in the presence of
methanol. The GAP promoter is useful for expression of foreign proteins that do not adversely
affect culture growth because it does not require any special induction strategy. Such cultures
can be grown to high density in glucose or glycerol and they express the gene product throughout
the fermentation. Protein expression based on the K. lactis platform often uses the galactoseinducible β-galactosidase gene promoter LAC4, which, like AOX1, is repressed by other carbon
sources.
Use of an inducible promoter provides tight control over recombinant protein expression,
which can be useful for the production of toxic proteins; however, this strategy requires careful
control of carbon compounds that are available. The AOX1 promoter is only induced by
methanol and is repressed to varying degrees by many sugars and alcohols including glucose,
ethanol (by conversion to acetate), and glycerol. Typically, fermentation of yeast using an
inducible promoter begins with rapid culture expansion using glycerol as the carbon source
followed by induction in the absence of glycerol. Supplementation of culture media with
monosodium glutamate (MSG) can improve culture growth without repressing recombinant
protein expression. Reducing sugars such as glucose and galactose must be autoclaved
separately from BSM containing primary amines to prevent Amadori or Maillard reactions;
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however, non- reducing carbon sources like the sugar alcohols glycerol and sorbitol do not react
with primary amines and can be included in the BSM prior to autoclave sterilization. Sorbitol
has been shown to improve protein expression when used as a cofeed with methanol during the
induction phase of growth (Holmes et al. 2009; Wang et al. 2010).

Oxygen Sources
Although comparative investigations of the effects of various gas mixtures on
recombinant expression have not been reported and the effects of excess O2 are unclear, the
availability of dissolved O2 gas is fundamental to yeast culture growth. Because all of the
potential pre-induction carbon sources are catabolized through the central glycolytic pathway,
the yeast cells require sufficient oxygen for aerobic respiration at all times to prevent the
accumulation of anaerobic ethanol and acetate that will inhibit recombinant expression driven by
the AOX1 promoter (Inan and Meagher 2001). For Muts (including strain KM71H) or Mut+
(including strains X-33, GS115 or SMD1168H) P. pastoris as well as all strains of K. lactis, the
same rationale applies to the induction phase.
In the case of Mut+ P. pastoris fermentation, the cells metabolize methanol like the wildtype and consume large amounts of methanol during the induction phase; furthermore, methanol
catabolism requires oxygen during two phases (Veenhuis et al. 1983; Cereghino and Cregg
2000). First, the conversion of methanol to formaldehyde by alcohol oxidase is directly
dependent on oxygen and methanol will accumulate to lethal levels in the prolonged absence of
sufficient oxygen. Second, the subsequent conversion of formaldehyde to CO2 is a 2-step
oxidation accompanied by the total reduction of 2 NAD+ to 2 NADH that then drive aerobic
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respiration. In the event of oxygen depletion, NADH cannot be oxidized to replenish the NAD+
pool sufficiently to prevent the toxic accumulation of intracellular formaldehyde.

Figure A1: Catabolism of Methanol. The catabolism of methanol is a three step process that
requires oxygen, both directly in the oxidation of methanol to formaldehyde and indirectly in the
oxidation of NADH by the electron transport chain (e- Transfer) to replenish intracellular NAD+.
Muts strains, such as KM71H, grow slowly on methanol because the AOX1 gene has been
disrupted and the cells must use the weaker AOX2 gene for methanol metabolism.

Nitrogen Sources
Bioavailable nitrogen is provided as ammonium (NH4+), either in the form of ammonium
hydroxide or ammonium sulfate. The choice of nitrogen source for the growth media depends on
the acidity of the initial solution. For media formulated with phosphoric acid, such as BSM, the
amount of ammonium hydroxide required to increase the pH supplies sufficient initial nitrogen
content for the yeast. Other media may use less acidic phosphate sources like potassium
phosphate or sodium hexametaphosphate (SHMP) that do not require neutralization by
ammonium hydroxide. In these cases, the media must be supplemented with ammonium sulfate
as it provides a nitrogen source without affecting the pH. Regardless of the initial formulation,
metabolically active P. pastoris continuously acidify the culture media and consume nitrogen
during fermentation; consequently, the bioreactor monitors the culture pH and can be set to
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automatically add ammonium hydroxide to maintain the desired pH while feeding the cells
nitrogen.

Phosphate Sources
The BSM recipe includes phosphoric acid as the source of bioavailable phosphate
whereas the FM22 medium uses monobasic potassium phosphate. While these compounds
affect the pH differently and determine which nitrogen source to include, they both contain
inorganic orthophosphate, PO43-. The PO43- ion is required by all organisms and must be
abundant for successful fermentation; furthermore, orthophosphate provides a pH buffer for the
growth media. Unfortunately, many salts of orthophosphate exhibit poor solubility, including
calcium, iron, and zinc salts. Fermentation media made with orthophosphate typically contain
some insoluble phosphate salts and the amount depends on the temperature and pH of the
solution as well as the calcium, iron, zinc, and phosphate concentrations. Because the PTM1
trace salts solution contains more ferrous sulfate and zinc chloride than PTM4, fermentation
media containing PTM1 typically develop more insoluble precipitate than those containing
PTM4.
Sodium hexametaphosphate (SHMP, or “phosphate glass”), (NaPO3)6, can be substituted
for orthophosphate to prevent the formation of insoluble salts; however, SHMP does not buffer
pH effectively and decomposes into orthophosphate at elevated temperature. In media
formulations that use SHMP instead of orthophosphate, a suitable pH buffer such as MES is
suggested in order to facilitate bioreactor regulation of pH; however, acetate must be avoided as
a pH buffer because it represses the AOX1 promoter (Inan and Meagher 2001). SHMP must be
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sterilized separately by ultrafiltration and added aseptically after the sterile fermentation vessel
has cooled to prevent SHMP decomposition into orthophosphate.

Trace Elements and Other Supplements
The final fermentation media require a number of trace elements that are combined into a
filter-sterilized, concentrated supplement and added to cool, sterile BSM in the fermentation
vessel. The two most commonly used trace element supplements are PTM1 and PTM4 and these
formulations vary primarily in the relative concentrations of several components. PTM1 was
found to produce more insoluble precipitate at neutral to alkaline pH than PTM4, despite
additional calcium, likely because of the additional masses of ferrous sulfate and zinc chloride in
PTM1 that form insoluble orthophosphate salts in the media. It has been shown that increased
levels of biotin supplementation improve recombinant protein expression in P. pastoris (Jungo et
al. 2007).
While both PTM1 and PTM4 supplements contain biotin, it is suggested here that
additional biotin be provided. Similarly, fermentations of P. pastoris or K. lactis may or may not
benefit from a supplementary vitamins mix, made as a 100x concentrate containing 0.1 g/L LHis-HCl, 0.2 g/L DL-Met, 0.2 g/L DL-Trp, 0.0002 g/L biotin, 0.0002 g/L folic acid, 0.2 g/L
inositol, 0.04 g/L niacin, 0.02 g/L p-aminobenzoic acid, 0.04 g/L pyridoxine HCl, 0.02 g/L
riboflavin, 0.04 g/L thiamine HCl, 0.04 g/L calcium pantothenate, 10 g/L CaCl2. These optional
supplements do not impair but may improve culture growth and protein expression; furthermore,
they are components of the Yeast Nitrogen Base (YNB) generally used in many yeast media.
Bioavailability of free amino acids in the fermentation media may improve secreted
recombinant protein expression by reducing the demand for amino acid biosynthesis and
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alleviating the drain placed on the cellular amino acid pool by the overexpression of recombinant
proteins. Proteins directed for secretion into the growth media may be susceptible to inactivation
or degradation through the actions of secreted neutral proteases and amino acid supplementation
of the media may reduce the expression of these yeast proteases. Casamino acids are one option,
but they are a complex mixture of amino acids and peptide fragments from the acid hydrolysis of
casein. As an alternative, a mixture of pure amino acids can be assembled with a known,
controlled composition.

Fermentation Medium and Bioreactor Setup and Assembly
Prior to culture growth, the sterilization and assembly of the fermentation medium and
the bioreactor vessel must occur. This process consists of 3 sequential phases of assembly, based
on sterility and temperature, where each phase includes a prescribed set of steps required for
correct fermentation conditions and bioreactor operations. The procedures described here
demonstrate the use of the BioFlo® 110 Bioreactor (New Brunswick) but also apply to other
similar apparatus.

Setup Phase 1: Presterile Assembly
Initial Medium Preparation. To begin, the initial components of the fermentation
medium are solubilized into deionized water and added into the fermentation vessel. The initial
volume for a 7.5 L vessel should be approximately 2.5-3.0 L of medium containing enough of
each ingredient per liter for 3.5 L of total medium.
The synthetic fermentation media formulations tried during the production of
recombinant enzymes described in Chapters 2, 3, and 4 are variations based on the BSM recipe
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recommended by Life Technologies and the FM22 recipe created by Stratton et al. (Stratton et al.
1998). The formulae of these media are provided in Table A1, above. Some formulations are
supplemented with 10 g/L monosodium glutamate (MSG) (Boettner et al. 2002).
Provided that the phosphate source is an orthophosphate like phosphoric acid or
potassium phosphate, it can be included at this time. SHMP must be filter sterilized and added
during setup phase 3 because it decomposes into orthophosphate at elevated temperatures. A
nonreducing carbon source like glycerol can also be included here; however, reducing sugars
such as glucose and galactose must be autoclaved separately and added during setup phase 3.
If the phosphate source is phosphoric acid, then no nitrogen source is required in the initial
solution; however, 5 – 10 g/L ammonium sulfate should be included if the phosphate source is a
potassium salt.
Bioreactor Setup and Sterilization. The fermentation vessel containing the initial medium
preparation is assembled with the head plate and rubber seal seated securely. During heat
sterilization, all head plate openings into the container must be sealed with the exception of the
exhaust tube, which should be stoppered with a gauze plug. For the external opening of the
metal oxygen sparging pipe, polymer tubing such as Tygon® should be attached, with a slip knot
tied tightly in the free end; otherwise, pressure from the heated gas in the vessel will push liquid
out through this opening. All other metal ports that open into the interior of the vessel should be
similarly sealed with knotted tubing. An image of the head plate, prepared for autoclave
sterilization, is shown (Figure A2).
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Figure A2: Bioreactor Vessel Head Plate. The bioreactor head plate is shown, from above,
immediately prior to autoclave sterilization. All important components of the head plate are
labeled. All ports that expose the vessel interior are “capped” or “plugged” and all ports that do
not expose the vessel interior are “open.”

The bioreactor makes use of a dissolved oxygen (dO2) sensor to monitor the percentage
of dissolved oxygen in the media, relative to a calibrated range of dO2 content. This metal probe
must be handled very carefully to avoid damaging the exposed membrane at its tip; however, it
can be mounted in the head plate prior to the subsequent sterilization of the vessel. The
calibration of this probe occurs during setup phase 3. The probe contains an electrolyte solution
that may require infrequent replenishment and a bottle of this is provided by the manufacturer.
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The pH probe can be mounted in the head plate prior to autoclave treatment; however,
this probe must be calibrated using standardized pH buffers prior to sterilization. As an
alternative, the pH probe can be sterilized with ACS methanol immediately prior to insertion into
a sterile vessel. The calibration of this probe requires standardization to two set points, “zero” at
pH = 7.0 and “span” at pH = 4.0.
Autoclave sterilization proceeds on a liquid cycle lasting 30 minutes at 121 °C.

Setup Phase 2: High Temperature Sterile Assembly
Once the fermentation vessel and medium have been heat sterilized, the vessel’s closedcircuit coolant piping is connected to an external liquid cooling unit containing antifreeze. This
cooling unit is turned on and set to 25 °C; furthermore, care must be taken to ensure that the
coolant reservoir is full and that all air is bled from the coolant lines because this can impede
proper temperature regulation. A temperature sensor connected to the bioreactor control module
(“the tower”) is inserted into a metal pipe that extends into but does not open on the interior of
the vessel. Until the vessel and medium have completely cooled, the oxygen sparger tubing
should remain tied and the exhaust tube should remain plugged with gauze. The electrical
impeller motor can be mounted on the impeller driveshaft and connected to the tower, ensuring
that the rubber seal of the driveshaft is always well-lubricated with vacuum grease. The impeller
can be set at low speed (≤ 350 rpm) to reduce vessel cooling time or the vessel can be allowed to
cool overnight. If the pH probe was not calibrated and inserted prior to vessel sterilization, this
should be done now. The dO2 probe must be connected to the tower and allowed to polarize for
a minimum of six hours prior to calibration in setup phase 3.
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Setup Phase 3: Final Assembly
After the vessel has cooled to between 25 °C and 30 °C, the oxygen sparger tubing can be
connected to the oxygen supply tank via a regulator, an airflow meter, and a 0.22 µm in-line
filter. The exhaust tube can be connected to the liquid cooled exhaust condenser that is attached
to tubing that bubbles exhaust gas through dilute chlorine bleach in an Erlenmeyer flask. The
sampling apparatus is mounted on the head plate and connected by tubing to the metal sampling
pipe. The impeller should be set at 350 rpm. Images of the connected bioreactor vessel (Figure
A3) and bioreactor control tower (Figure A4) are shown.

Figure A3. Bioreactor Vessel. The bioreactor vessel is shown that illustrates the connection of
the assembled fermenter. The impeller motor has been mounted on the impeller driveshaft. The
impeller motor, pH probe, dO2 probe, and temperature sensor are connected to the bioreactor
control tower (see Figure A4). The air inlet hose, the exhaust hose, and the main coolant lines
are obscured in this image. Refer to Figure A2 for locations of these ports.

179

Figure A4. Bioreactor Control Tower. The bioreactor control tower is shown with all
connections to the bioreactor vessel (left). The pump head contains four peristaltic pumps
regulated by the control tower. These pumps can be programmed to feed acid, base, antifoam, or
other agents either at constant rates or in response to pH and foam sensors. A separate pump is
used for delivering the carbon feed for improved volumetric regulation of the feed rate. The
bioreactor control tower is modular and can be arranged in other ways. The digital interface unit
(computer) for the control tower is stacked above the dO2/pH probe inputs and cannot be seen in
this image (see Figure A5).

Final Medium Assembly and pH adjustment. The remaining components of the
fermentation medium are added aseptically at this time into the stirring fermentation vessel. The
trace elements solution (e.g. PTM1 or PTM4) is added to the appropriate final dilution. Extra
sterile components such as biotin, a vitamins mix, amino acid supplements, SHMP, and reducing
sugars can also be added at this time. Once these components have been added, the bioreactor is
setup for pH control.
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Figure A5. Bioreactor Digital Interface. The digital interface of the control tower is shown.
This computer monitors and displays sensor data in real-time. The context-specific buttons make
selections as indicated adjacently on the digital screen.

The tower can be programmed through the digital interface to activate acid and/or base
feed pumps in response to deviations of culture pH from the set point. An image of the digital
interface (Figure A5) is shown for reference, see the bioreactor user’s manual for details. In the
case of P. pastoris, the growing culture acidifies the media; consequently, the base pump is setup
to provide a regulated drip feed from a reservoir of ACS ammonium hydroxide diluted 1:1 into
deionized water. The tubing from the base pump is connected to the head plate of the
fermentation vessel. Only then is the tower set to regulate the pH and the pump turned on. If the
pH of the broth is below the desired set point, then the bioreactor will add ammonium hydroxide
at this time to adjust the pH. Culture pH affects the activity of extracellular proteases that can
degrade recombinant protein secreted into the medium. The unwanted activity of neutral
proteases can be prevented by the addition of broad spectrum protease inhibitors or reduction of
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the culture pH when inhibitors are undesirable; consequently, P. pastoris fermentations are
frequently conducted at pH < 5.0, especially during induction.
dO2 Probe Calibration. To ensure proper monitoring of the dissolved oxygen content of
the culture, the dO2 probe must be calibrated. First, the “zero” set point is established. This can
be accomplished by disconnecting the probe from the tower just long enough for the raw reading
to stabilize (about 2 seconds) or by sparging the medium with pure nitrogen gas until the raw
reading stabilizes. After the minimum raw reading has been reached, the “zero” set point is set
to 0 %. Second, the “span” set point must be established. For this, the oxygen flow rate is set to
1 vvm (volume of gas per volume of culture per minute), e.g. 3.5 LPM (liters per minute) of
oxygen for a 3.5 L liquid volume, and the impeller motor is set to its highest speed (1200 rpm for
a New Brunswick BioFlo-10 bioreactor). The fermenter must then be left undisturbed until the
raw reading reaches a stable maximum, approached asymptotically, at which point the “span” set
point is entered as 100.0 %, representing the maximum amount of oxygen driven into solution at
equilibrium by the given gas supply under maximum stirring conditions. Physical chemistry
dictates that the equilibrium of dissolved O2 at constant temperature and pressure is directly
proportional to both the partial pressure of O2 in the gas and the surface area of the gas/liquid
interface; consequently, pure oxygen and maximum stir rates maximize the absolute amount of
O2 dissolved at equilibrium. Once the probe is calibrated, the O2 supply can be turned off until
the culture is inoculated.
Throughout the fermentation of yeast, assessments of culture health and metabolism rely
on the careful observation and accurate interpretation of changes in dO2 content and impeller
behavior because the respiration reflects carbon consumption, both critical components for high
yield culture expansion and protein production.
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Yeast Fermentation
Bioreactor based fermentation of yeast using a repressible/derepressible transcriptional
promoter like AOX1 and LAC4 consists of four culture growth stages: inoculum growth, preinduction batch phase, pre-induction fed-batch phase, and induction fed-batch phase. The
culture inoculum expands while consuming the available carbon during the preinduction batch
phase. Upon carbon depletion, the pre-induction fed-batch phase further increases the culture
density with the drip-fed addition of concentrated pre-induction carbon source at a regulated rate.
A culture of sufficient density is then transitioned to a drip-feed of the carbon source required for
the induction fed-batch phase. Yeast transformants using a constitutive promoter only require a
batch phase followed by a fed-batch phase, with no distinction based on induction; however, the
general procedures remain the same.

Inoculum Growth
Two days prior to fermenter inoculation, a 10 mL liquid seed culture of the yeast is set to
grow with shaking at 30 °C overnight in YPD with antibiotics (100 µg/mL Ampicillin and, for P.
pastoris, 100 µg/mL Zeocin) to which the strain is resistant. On the day before fermenter
inoculation, the starter culture in a nutrient-rich synthetic minimal medium (SMM) is seeded
from the YPD culture. This starter culture is grown for 24 – 36 hours with shaking at 30 °C in a
1 L baffled shaker flask that is filled approximately 1/3 with SMM containing the pre-induction
carbon source, often glycerol. The starter culture should be grown to high density and the
volume of inoculum should not exceed approximately 10 % of the initial fermentation volume.
Inoculation of the fermentation vessel proceeds only after the completion of bioreactor
setup and assembly. The entire starter culture volume is added aseptically to the fermentation
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vessel and a 25 ml sample is immediately withdrawn and centrifuged to determine the wet cell
pellet weight (WCW) in grams per liter of medium. Throughout the fermentation process, such
25 ml samples will be collected at least once per day and at the start of every phase of
fermentation; furthermore, the WCW data should be graphed over time to monitor the health and
growth rate of the culture, which should continue to expand throughout the fermentation.

Preinduction Batch Phase
Once the fermentation vessel has been inoculated, the culture enters the pre-induction
batch phase, during which it consumes the supply of bioavailable carbon in the broth. At the
time of inoculation, the bioreactor control tower should be set up to automatically regulate the
dO2 by adjusting the impeller speed. The dO2 set point should be no less than 35 % to ensure
that the actual dO2 of the culture does not drop below 20 %; furthermore, the impeller speed
range should be set between a minimum of 350 rpm and the maximum allowable speed (1200
rpm for a New Brunswick BioFlo-10 bioreactor) for automatic speed control.
The starting dO2 will likely be above 95 % due to saturation from probe calibration. As
the culture grows, the dO2 will gradually fall until it drops below the dO2 set point, at which
time the impeller speed will be automatically increased to compensate for the increased oxygen
demand. Changes in the dO2 content of the medium reflect the metabolic health of the culture
and the bioavailability of carbon; consequently, careful dO2 monitoring throughout all stages is
critical to successful fermentation.
The preinduction batch phase lasts until the culture has depleted the bioavailable carbon
in the growth medium. The end of this phase is marked by a reduced oxygen demand of the
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yeast in response to the lack of carbon and a significant increase of the dO2 above the
programmed set point, despite a reduction in impeller speed to its minimum.

Preinduction Fed-Batch Phase
At this time, a steady pump-fed, drop wise addition of the pre-induction carbon source is
initiated. A sterile solution of 50 % glycerol in deionized water is recommended with a feed rate
of 1 mL/min (Bio-Rad Econo peristaltic pump) for a 3.5 L culture volume (17 – 18 mL/hr per
liter of initial volume). The culture will respond to the addition of fresh bioavailable carbon by
increasing the oxygen demand, as evinced by a steady reduction of dO2 and an increased
impeller speed. This phase lasts until the culture density has reached a wet cell pellet weight
(WCW) of 180 – 200 g/L, approximately 4 – 6 hours.
By the end of the preinduction fed-batch phase and throughout the rest of the
fermentation, the culture should also be carbon limited, with a carbon consumption rate equal to
the carbon addition rate so that no excess feed accumulates in the medium. A carbon limited
culture runs out of carbon source very shortly after the drip feed is turned off and this results in a
rapid increase in dO2 (a dO2 spike), usually within two minutes. Carbon limitation at the end of
the pre-induction fed-batch phase ensures that no promoter repressing carbon compounds
interfere with the induction phase.

Induction Fed-Batch Phase
A carbon limited yeast culture of WCW = 180 – 220 g/L is ready for induction, which is
initiated simply by changing the carbon feed. In the case of P. pastoris controlled by AOX1, the
transition to methanol must occur in stages to allow the yeast time to adapt. The initial feed rate
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of pure methanol, 3.6 mL/hr per liter of initial fermentation volume, is maintained for 3 – 4
hours, until the dO2 holds steady and dO2 spikes occur quickly. At this time, the methanol feed
rate is doubled to 7.2 mL/hr per liter of initial volume and maintained for 2-3 hours, after which
the culture is tested again for carbon limitation by the dO2 spike method. If a dO2 spike occurs
shortly after terminating the methanol feed, then the culture is carbon limited and the feed rate is
increased to 10.9 mL/hr per liter, where it remains until the end of fermentation. The induction
fed-batch phase usually lasts for about 72 hours, with an average feed rate of 10.4 mL/hr per
liter. These feed rates follow the recommendations of the Life Technologies Pichia
Fermentation Process Guidelines. Not all transformants will produce proteins optimally under
these conditions; consequently, the feed rates and fermentation time may require adjustment to
maximize protein production.
It has been shown that supplementation of the methanol feed with sorbitol improves
culture growth and protein yields (Holmes et al. 2009; Wang et al. 2010). Because it does not
dissolve in pure methanol, sorbitol should be fed through a separate line rather than dissolved
into methanol diluted with water. Diluted methanol requires a faster feed rate than pure
methanol to provide the same amount of carbon, which dilutes the culture and reduces the
growth rate; furthermore, the volume of water added to the fermentation during fed-batch phases
should be minimized to prevent the culture volume from exceeding the capacity of the vessel.
Carbon limitation should be evaluated periodically throughout the induction fed-batch
phase to ensure that methanol does not accumulate in the vessel over time, as excess methanol is
toxic. To verify that the culture is carbon limited, the drip feed is stopped and the time to the
dO2 spike is observed by monitoring both the dO2 reading and changes in the impeller speed. It
is important to confirm that an increase in dO2 is actually a spike and not just in response to an
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increase in the impeller speed. For a true spike, the dO2 will continue to rise even as the impeller
speed falls.

Culture Harvest
After completion of the induction fed-batch phase, the culture is harvested from the
fermentation vessel. Although several approaches are available for recovering the culture
volume, the use of oxygen pressure is suggested to drive the broth out through the sample
collection tube. This can be achieved by clamping the exhaust tubing, unclamping the sample
collection tubing, and collecting the stream of liquid directly into centrifuge bottles, which
minimizes the amount of clean up that is required. The yeast should be centrifuged with a
relative centrifugal force of 5,000 – 10,000 x g for 10 – 20 minutes or until all cells have formed
a pellet. For proteins that are retained by the yeast, the cells can be lysed by a variety of methods
including mechanical disruption (e.g. glass beads), enzymatic treatment (e.g. lyticase), repeated
freeze/thaw cycles, sonication, or the use of a French pressure cell. For proteins secreted by the
yeast, the culture supernatant is further clarified after separation from the cell pellet. The
supernatant can be passed through glass fiber prefilters as well as submicron filter membranes
made of low protein binding materials like polyethersulfone (PES).
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